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Abstract
Carnosol, a naturally occurring phytopolyphenol found in sage, oregano and rosemary,
has been extensively studied by our laboratory for its anticancer effects in various types
of cancer. In human Triple Negative Breast Cancer (TNBC), carnosol was shown to
inhibit cellular viability, colony growth, induced cell cycle arrest, autophagy, and
apoptosis. Nonetheless, very little is known about molecular mechanism of action. In
the current study, the ability of carnosol to inhibit metastasis and tumor growth was
examined. Wound healing and invasion assays revealed that carnosol inhibited
migration and invasion at non-cytotoxic concentrations of MDA-MB-231 cells. Also,
carnosol found to inhibit the activity and downregulated the expression of MMP-9.
Activation of STAT3, a transcription factor that regulates MMP-9 expression, was also
inhibited via carnosol-mediated ROS-dependent proteasome degradation. In vivo study
using chick embryo tumor growth assay has shown that carnosol significantly and
markedly suppressed tumor growth and metastasis of breast cancer xenografts.
Additionally, we found that carnosol induce ROS-dependent, p38-dependent ER stress
and activates UPR via upregulating the ER stress sensors (ATF4/CHOP, ATF6⍺, and
IRE1⍺/XBP1). Also, upstream triggers of Unfolded Protein Response (UPR) pathway,
β-catenin and ER stress chaperones, were upregulated. On the other hand, cell survival
Akt/mTOR signaling pathway was downregulated in a ROS-dependent manner. We also
found that carnosol targeted p300 and PCAF Histone Acetyltransferases (HATs) to
proteasome degradation through a ROS-dependent mechanism. Interestingly, using a
cell-free system, we show for the first time that carnosol efficiently and selectively
inhibited histone acetyltransferase activity of p300 while having no effect on the other
HATs such as PCAF and GCN5. This work provides further confirmation that carnosol
represents a promising anti-breast cancer therapeutic compound and identifies it as a
novel natural p300 inhibitor that could be added to the existing panel.

Keywords: TNBC, metastasis, tumor growth, STAT3, ROS, UPR, p300,
acetyltransferase activity.
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)Title and Abstract (in Arabic

آلية العمل الجزيئية للمركب الطبيعي المتعدد الفينول ومانع " P300كارنوسول" ضد
سرطان الثدي السلبي الثالثي
الملخص

الكارنوسول هو مركب فيتوبوليفينول موجود طبيعيا ً في بعض النباتات كالمرمية والزعتر وإكليل
الجبل ،تمت دراسة تأثيره على أنواع مختلفة من السرطانات .في سرطان الثدي الثالثي السلبية
( ،)TNBCثبت أن الكارنوسول يثبط تكاثر الخاليا السرطانية ونمو المستعمراتها ،كما أنه يوقف
دورة الخلية ويؤدي إلى موتها إما بااللتهام الذاتي او الموت المبرمج .ومع ذلك ،ال يُعرف سوى
القليل جدًا عن آلية عمل الكارنوسول الخلوية والجزيئية .في هذه الدراسة الحالية ،تم تقييم قدرة
الكارنوسول على تثبيط انتقال الخاليا السرطانية من عضو إلى أخر( )metastasisوأيضا ً نمو
الورم الخبيث ،كما أنه تمت دراسة تأثير الكارنوسول ونقص الحمض الميني األستيل على
بروتينات الهيستون في المختبر والجسم الحي .كشفت التجارب المختبرية في الدراسة الحالية
الكارنوسول قادر على تثبيط انتقال وغزو الخاليا السرطانية وأيضا ً نمو الورم الخبيث عن طريق
تجربة ألتام الجرح وغزو الجيالتين .إضافة إلى ذلك ،كشفت تجارب الجيالتين زيموغرافي
( )gelatin zymographyواالنزيم المرتبط بالمناعة ( )ELISAوالنسخ العكسي لمتفاعل
المتسلسل البوليميرازي ( )RT-PCRأن الكارنوسول قادر على تثبيط تعبير ونشاط .MMP-9
بروتين معامل االستنساخ  STAT3له دور كبير في التحكم في التعبير البروتيني ل ،MMP-9
لذلك تم اختبار تأثير الكارنوسول عليه وأظهرت النتائج انه تعبير ال  STAT3تم تثبيطه بواسطة
تواجد االكسجينات التفاعلية  ROSالمحفزة بواسطة الكارنوسول .إضاقة إلى ذلك ،تم اختبار
الكارنوسول على نمو الورم الخبيث في أجنة الفراخ ،وأظهرت النتائج قدرة الكارنوسول على
إحباط نمو الورم بشكل ملحوظ .وفي الجزء اآلخر من البحث ،أثبت الكارنوسول قدرته على
إحداث إجهاد الشبكة االندوبالزمية ) (ER-stressالذي يؤدي إلى تفعيل مسار االستجابة
للبروتينات المتدمرة  UPRعن طريقة ازدياد التعبير البروتيني ل ATF4/CHOP,
ATF6⍺و  .IRE1⍺ /XBP1عالوة على ذلك β-catenin ،والبروتينات المرافقة إلجهاد
الشبكة االندوبالزمية  ،chaperonesتم ثبيط تعابيرهم البروتينه بواسطة الكارنوسول .وفي الجهة
المقابلة قام الكارنوسول بتخفيض اإلشارات الحيوية عن طريق ثبيط بروتينين .Akt / mTOR
كما اثبتت التجارب أن الكارنوسول قادر على تنظيم موت الخاليا السرطانية عن طريقة تحفيز
التعبير البروتيني ل . P38وفي الجزء األخير من الدراسة أظهر الكارنوسول قدرته على تحفيز

ix

نقص الحمض الميني األستيل على بروتينات الهيستون عن طريق إحباط البروتينات المسؤولة
كال  P300وPCAFخصيصا ً وذلك اعتمادا ً على تواجد االكسجينات التفاعلية  .ROSوفي الختام
تقدم هذه الدراسة دليالً على أن الكارنوسول قد يمثل مرش ًحا عالجيًا واعدًا يعالج انتشار ونمو ورم
سرطان الثدي وكمثبط طبيعي جديد كال .P300
مفاهيم البحث الرئيسية :سرطان الثدي الثالثي السلبية ،نمو الورم الخبيث ،STAT3 ،االكسجينات
التفاعلية ،p300 ،إجهاد الشبكة االندوبالزمية ،الحمض الميني األستيل.
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Chapter 1: Introduction
1.1 Breast Cancer
Over the past five decades, deaths from heart disease, stroke, and pneumonia have
dropped because of the newly developed treatments and preventive approaches based
on a profound understanding of these diseases’ risk factors and pathogenesis. At the
same period, cancer mortality relatively has not changed

[1]

. We are currently at a

turning point in history in which cancer deaths exceed those from cardiovascular
diseases [2,3].
Cancer is a multifactorial disease that begins when cells divide uncontrollably and
spread into nearby tissues

[5]

. In 2020, breast cancer was the leading cause of death

among women globally. Breast cancer remains the fifth most common cancer in terms
of incidence and mortality, presenting 11.7% of total incidence and the 6.9% of total
deaths

[6,7]

. In the United Arab Emirates, breast cancer presents 21.4% (1030 out of

4807) of all cancer types and 11.8% (222 out of 1896) of cancer deaths

[8]

. The

recorded number of cases in 2020 was 1030 and is expected to increase to 2310 by
2040. The burden of breast cancer incidence and mortality is obviously increasing,
exceeding all other cancers worldwide [9]. Therefore, it is urgently needed to discover
efficient treatments for breast cancer.
Breast cancer is a heterogeneous disease, which makes it challenging to diagnose and
treat

[9]

. Currently, breast cancer is mostly classify based on the proliferation index

(Ki67) and expression of hormone receptors, including estrogen receptor (ER),
progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2).
Accordingly, there are four molecular subtypes of breast cancer which are luminal A

2
(ER+ /PR+ /Ki67 low <14% or Ki67 intermediate 14–19%), luminal B (ER+ /PR+
/HER2–/+ /Ki67 intermediate 14–19% or Ki67 high > 20%), basal-like or triplenegative (ER–/PR–/HER2–/Ki67) and HER2 overexpressing (ER–/PR–/HER2+/Ki67)
[10–13]

.

1.1.1 Triple-Negative Breast Cancer
Among these, TNBC that lack the expression of the three main hormonal receptors,
accounts for approximately 15% to 20% of all breast cancer types [14], frequently occur
in younger (<50 years) women and are more prevalent in Hispanic and African
American women [15]. TNBC exhibits increased proliferation markers, mitotic activity,
high-grade nuclear atypia, scant stromal content, high nuclear cytoplasmic ratio,
central necrosis, multiple apoptotic cells, invasive, and stromal lymphocytic
infiltration

[16,17]

. Moreover, TNBC is characterized by a rapid growth rate, higher

grade compared to other breast cancers, lymph node progression, and can metastasize
to other organs, mostly, lungs and brain

[18]

. TNBC was also found to have a poor

prognosis, very aggressive, high reoccurrence rate, and shorter survival period
[9,10,19,20]

. This is because it lacks the hormonal receptors’ expression, thus cannot be

efficiently targeted by endocrine therapy (e.g., tamoxifen, aromatase inhibitors) and
HER2-directed therapies (e.g., trastuzumab) [21]. TNBC is a heterogeneous disease by
itself, constitutes different molecular subtypes that can vary in response to therapy.
The current treatment of TNBCs mainly relies on chemotherapy; however, this
treatment face resistances and metastasis occurs

[22]

. Consequently, this makes it

challenging for the clinical management and current treatments. Hence, new targeted
therapeutic approaches for TNBC are an unmet need.

3
1.2 Phytochemicals with Therapeutic Potential Against TNBC
TNBC is the most aggressive form of breast cancer, and the incidence of new cases
and mortality is rising worldwide. Due to the lack of specifically known targets and
targeted treatments, TNBC develops a high tendency to drug resistance and
metastasize to lung, bone, and brain, making it very challenging to treat

[23,24]

.

Currently, TNBCs are treated with chemotherapy agents alone or in combination with
radiotherapy or surgery [25]. The current use and approved chemotherapeutic agents for
TNBC include cisplatin, anthracycline, taxanes, paclitaxel, tamoxifen, and platinum
compounds

[22,26,27]

. However, besides the other conventional therapies, these

chemotherapeutics approaches made the patients suffer from severe side effects, and
develop resistance to them with time [28]. Identifying a new novel anticancer drug to
treat TNBCs is relatively considered an expensive approach. Henceforward, we
observed that the current focus is leaning towards using plant-derived compounds (also
called phytochemicals) treatment options. Because they are more convenient to use,
have lower cost, exhibit less toxicity, more effective, and with reduced side effects,
thus, the use of phytochemicals for treating TNBC patients is a promising option.
Phytochemicals have been used for medicinal purposes since the origin of humanity.
Due to the convenient and beneficial properties of phytochemicals (like effective,
cheaper, and less toxic), employing them for TNBC therapy can be a vital strategy and
improve the life quality of TNBC’s patients

[29]

. Several phytochemicals displayed

anticancer activity against TNBC and other cancers, such as resveratrol, indole-3carbino, fisetin, 6-gingerol, curcumin, capsaicin, and quercetin. This is because they
target several molecular pathways in carcinogenesis, including apoptosis,
proliferation, cancer stem cells, inflammation, invasion, metastasis, angiogenesis, and

4
the likes [30–32]. Specifically, through the alteration of multiple cellular pathways like
TNF-ɑ, Notch, Wnt-ß, TGF-ß, Ras, EGFR, INF-γ, and hedgehog which are implicated
in tumor development [33]. Several researchers reported promising anticancer activity
of phytochemical either alone or in combination with a chemotherapeutic drug.
The increased virulence of triple-negative tumors might be attributed to the increases
in the expression and activity of vascular endothelial growth factor (VEGF). VEGF is
a major angiogenic factor known to promotes tumor growth and metastasis, leading to
higher morbidity

[34,35]

. Hence, VEGF-stimulated proliferation and migratory

pathways make it a good target of adjunctive chemotherapy. Luteolin is a
phytochemical (a flavonoid commonly found in many vegetables, fruits, and medicinal
herbs) that inhibits VEGF expression and suppresses the proliferation of several cancer
cells. It can also restrain invasion, metastasis, angiogenesis, reverse epithelialmesenchymal transition (EMT) and induce apoptosis

[36–38]

. For that reason, Cook et

al. evaluated the effect of luteolin against TNBC and studied its potential to reduce
metastasis and tumor growth. In vivo studies showed that luteolin suppresses lung
metastasis of triple-negative cell lines (MDA-MB-435 and MDA-MB-231) to the lung,
in which metastasized TNBC colonies were reduced from ~14% to ~5%. Further, the
in vitro experiment revealed that luteolin significantly reduced cell viability at a
concentration > 10 μM, induced apoptosis, and VEGF secretion was significantly
inhibited [39].
Morover, several studies have reported promising synergistic effects of combining
phytochemical with the chemotherapeutic agent to treat cancer. In that case, piperine
is an alkaloid phytochemical, which shows anticancer activity through suppressed
TNF-α mediated cellular processes, activate NF- Кb and expressed cell adhesion
molecules, and blocked VEGF mediated tumor angiogenesis [40,41]. Henceforth, due

5
to piperine’s broad spectrum of anticancer activity, this makes it a potent adjuvant
to be used in combination with other anticancer chemotherapeutic agents

[42]

. This

is confirmed when Abdelhamed et al. screened many phytochemicals along with
TRAIL therapeutics, studying their synergistic activity against TNBC cell lines
(MDA-MB-468, MDA-MB-231, and 4 T1 [murine]) 42. Piperine was found to be the
best adjuvant candidate in combination therapy, in which it improves the efficacy of
TRAIL therapeutics against TNBC. The combination of piperine and TRAIL showed
more efficient induction of cytotoxicity, apoptosis, and cell cycle arrest than using
piperine or TRAIL alone to treat TNBC 42. Another study by Şakalar et al. investigated
the anticancer effect of combining the phytochemical thymoquinone (the active
ingredient in Nigella sativa) with the chemotherapeutic drug paclitaxel against the
mammary triple negative cells 4T1. Their data suggest that combination therapy of
thymoquinone + paclitaxel showed significant synergistic cooperation, in which
thymoquinone sensitizes 4T1 cells to paclitaxel through several signaling involving
p53, apoptosis, and tumor suppressor genes 43.

Therefore, considering discussed studies above, phytochemicals alone or in
combination with other chemotherapeutic drugs have substantial potential in targeting
numerous cascades in TNBC tumors. Exploring and identifying phytochemicals
besides the development of other therapeutics advances can serve as potential tools in
the future to decimate TNBC. Next, a promising phytochemical, carnosol, and its
potential to treat TNBC will be discussed.
1.3 Carnosol
Dietary phytochemicals have been appreciated to prevent and cure several lethal
diseases, including cancer

[43]

. Plant bioactive moieties include xanthonoids,

6
flavonoids, and terpenoids, in which terpenoids are considered one of the most
significant classes

[44]

. Carnosol is a polyphenolic phytochemical that belong to the

terpenoids class and is known to possess a range of therapeutic effects such as antiinflammatory [45], antioxidant [46], neuroprotective [47], antimicrobial [48], and anticancer
properties

[49,50]

. Talking about cancer, several studies have revealed the anticancer

effects of carnosol are through the inhibition of proliferation and survival, restrain
migration and invasion, and enhance apoptosis [50,51(p. 2),52]. All these anticancer effects
are mediated via modulating various signaling pathways, including apoptosis
(Bax/Bcl2/caspases), survival and proliferation (Akt/mTOR/MAPK), transcription
factors like NF-κB, STAT3-6, and other cellular pathways. The triple-negative tumor
is one of the most aggressive and hard to treat, and lately, few studies have reported
the effect of carnosol against TNBC. Here, the current section (1.3) will highlight the
source and chemical characterization (1.3.1), safety and toxicity (1.3.2), and existing
evidence examining the anticancer effects of carnosol against TNBC (1.3.3).
1.3.1 Carnosol’s Sources, Chemistry and Structural Characterization
Rosemary and sage are Mediterranean herbs used for culinary purposes and have been
known to contain various bioactive compounds, including polyphenols such as
carnosol, carnosic acid rosmanol, rosmarinic acid as well as others. Carnosol was
firstly isolated from sage (Salvia carnosa) in 1942, and its chemical structure
(C20H28O4) was first identified by Brieskorn et al. in 1964 [53]; Figure 1 illustrates the
carnosol structure and one example of plant source, sage. Carnosol, an orthodiphenolic diterpene with an abietane carbon skeleton with hydroxyl groups at
positions C-11 and C-12 and a lactone moiety across the B ring and considered as
result product from the oxidative degradation reaction of carnosic acid

[54,55]

. Its
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absorbance corresponds to λmax = 212, 285 nm. Carnosol is soluble in organic solvents
such as dimethyl sulfoxide (DMSO), ethanol, and dimethyl formamide, in which
solubility in these solvents is 250, 8, and 35 mg/ml, respectively

[54]

. Nowadays,

carnosol is receiving increasing attention for its various health-promoting properties.

Figure 1: Chemical structure of carnosol (left) found in sage (right).

1.3.2 Safety and Toxicological Studies on Carnosol
Toxicological studies are essential to develop therapeutic drugs for clinical use.
Several animal studies have suggested that the daily oral intake of carnosol is safe.
Johnson et al. revealed that carnosol at a dose of 30 mg/kg was well tolerated in mice
[49]

. Similarly, Sprague–Dawley rats were fed with an AIN-76A diet supplemented

with 1% carnosol for two weeks, and it showed no side effects on body weight

[56]

.

Agreeing with previous studies, Phipps et al. recently investigated the toxicity of
carnosol and carsonic acid using rosemary extract for 90 days in males and females
mouse models, and they found no adverse side effect for a high dose reaching 195
mg/kg body weight/day which is equivalent to 64 mg/kg body weight/day carnosol
and carnosic acid [57].
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Traditional herbal medicine has good therapeutic values; FDA has recognized
carnosol-enriched rosemary extracts as “Generally Recognized as Safe” (GRAS). This
study tested the toxicity of several herbal extracts, including rosemary, the dose range
was between 80 to 400 mg/kg/bw/day, which was equivalent to 20–60 mg/kg/day of
carnosol and carnosic acid per day, and there were no observable adverse effects on
the used animal models [58].

1.3.3 Effects of Carnosol on TNBC
Triple-negative is the most complicated to treat and the most fatal breast cancer type,
and the median of survival for metastatic patients is around one year

[59]

. The

phytochemical, carnosol, showed promising health-promoting activities [60] and there
are few studies in the literature review that have been demonstrated the anticancer
effects of carnosol on TNBC. Generally, carnosol has been reported to affect TNBCs
through reducing cellular viability, inducing apoptosis and autophagy, block the cell
cycle, inhibiting migration and metastasis, preventing tumor growth, and affecting
post-translational modification via inhibiting p300 acetyltransferase. Table 1
summarize studies that reported the effects of carnosol on TNBC.
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Table 1: Summary of studies that reported the effects of carnosol on TNBC.

Cell
line

Carnosol alone or in
combination (dose &
duration)
In
Alone
combination

MDAMB-231

10–
100
μM;
2–12 h

HBL100
MDA231
MDA435

12.5–
200
μM;
4 h, 24
h, 48 h
& 72 h

MDAMB-231

25–
100
μM;
24 h &
48 h

-

Carnosol 50
μM +
Curcumin 70
μM; 4 h

-

Experimental model
In
vitro

✓

✓

✓

In
vivo

-

-

-

Mechanism
of action

Targeted
proteins

Ref
.

In
silico

-

-

-

Carnosol
impaired the
proliferation
through
CYP1A1
reduction and
AMPK
activation.
Carnosol
alone
inhibited the
viability of all
TNBC cell
lines. The
combination
with curcumin
was tested
using MDA231, which
resulted in a
synergistic
reduction in
vitality,
apoptosis
induction, and
cell cycle
blockade.
Carnosol
reduced
viability,
block cell
cycle at G2
phase, induce
DNA damage,
reduce the
mitochondrial
potential,
cause ROSdependent
apoptosis
intrinsically
and
extrinsically,
induce beciln1-independent
autophagy,
and constrain
colony
growth.

↓ CYP1A1
↑ pAMPK
↓ AhR

[61]

↓ Cyclin
D1
↓ Bcl2
↓ Survivin
↑ p27

[62]

↑
p21/WAF1
↓ p27
↑ PARP
↑ Caspases
3,8,9
↓ Bcl2/ ↑
Bax
↑ LC3II
↓ p62
(SQSTM1)
↑ pERK1/2
↑ γH2AX

[50]
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Table 1: Summary of studies that reported the effects of carnosol on TNBC
(continued).

Cell
line

MDAMB-231

Carnosol alone or in
combination (dose &
duration)
In
Alone
combination
EC50
<9
μM

Experimental model
In
vitro

In
vivo

Mechanism
of action

Targeted
proteins

Ref
.

In
silico

✓

Carnosol
showed an
antiproliferati
ve effect

-

[63]

1.3.3.1 Carnosol Induces Cell Cycle Blockage
Cell cycle is a highly regulated and organized process that responsible for cellular
proliferation and growth via ensuring the duplication of genetic material and cell
division. This process comprises growth-regulatory signals as well as checkpoints
proteins that monitor the genetic integrity to ensure the absence of any genetic damage.
Cells reproduce through the progression into four distinct phases of the cell cycle;
G0/G1, S, G2 and M. Theses phases are controlled by a number of CDKs, that act in
complex with their cyclin partners (cyclin D, E and B), drive the cell forward through
the cell cycle. However, whenever an error exists in any of the cell cycle phases, CDK
inhibitors interfere to stop the cycle’s progression, either to fix it or to induce cell
death. The INK4 is class of CDK inhibitors, includes p16, p15, p18, and p19, which
bind and inhibit cyclin D–associated kinases such as CDK4, and 6. Another class of
CDK inhibitors is the kinase inhibitor proteins (KIP), involves p21, p27, and p57,
which negatively regulate cyclin E and A to bind to CDK1 CDK2 complexes [64,65].
Aberrant cell cycle activity and uncontrolled cellular proliferation are characteristics
of cancer cells. These results from mutations in upstream signaling pathways or
genetic lesions occur in genes encoding cell cycle proteins. Also, human cancers are
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seen with aberrant activation of CDKs

[66]

, therefore, finding inhibitors of CDKs and

cell cycle regulators are considered attractive targets in cancer therapy.
Most of the currently used anticancer drugs (like; tamoxifen and methotrexate

[67]

)

limit tumor progression by hindering one or more cell cycle phases and their transition
points, and consequently attenuate the cancer cell proliferation. Arresting of the cell
cycle by these drugs may also be associated with the induction with apoptosis

[68]

.

Importantly, several studies claimed that the anticancer effects of carnosol is via the
inhibition of cancer cell proliferation either via cell cycle arrest or induction of
apoptosis [69,70]. In a study utilizing TNBC cell line, MDA-MB-231, Al Dhaheri et al.
checked whether carnosol cytotoxic mechanism of action affect the cell cycle
distribution, the analysis showed that carnosol (50 and 100 µM) induced G2 cell cycle
blockade, this was confirmed with an overexpression of p21 (a CDK inhibitor)

[50]

.

Carnosol showed promising anticarcinogenic effects in triple-negative and other
cancers, yet further investigations are needed through utilizing in vivo animal models
in addition to the clinical studies to validate the usefulness of carnosol against cancer.
1.3.3.2 The Role of Carnosol in Inducing Cell Death Mechanisms
1.3.3.2.1 Carnosol Induces Apoptosis
Apoptosis is a type of programmed cell death that plays a vital role in maintaining
tissue homeostasis by eliminating damaged and unwanted cells. Apoptosis is an
evolutionarily conserved and highly regulated energy-dependent process that happens
discretely in individual cells of our body

[71]

. However, deregulation of apoptosis is

implicated in several pathological conditions, including cancer. Usually, cancer cells
resist and escape apoptosis by over-expressing the antiapoptotic proteins and

12
repressing tumor suppressor genes. Consequently, this led to cancer development,
progression, tumor growth, and develop treatment resistance [72,73]. TNBC is one of the
most aggressive cancer types known to evade apoptosis and develop resistance to
currently used therapeutic approaches (like; chemotherapy and radiotherapy). Even
though current treatments are acting via activating cell death pathways like apoptosis,
TNBC finds a way to relapse and develop resistance toward the treatment and
apoptosis, making it clinically challenging to treat and find targeted treatment for
triple-negative tumors

[74]

. Henceforth, a better understanding of the molecular

mechanisms underlying TNBC resistance to apoptosis will probably provide the basis
for a rational method to develop targeted molecular therapies.

Carnosol is one among the polyphenols reported to have anticancer effects against
several kinds of human cancer cell lines and animal models

[75]

. Due to the high

challenges facing treatment for triple-negative, this attracted the interest of Al
Dhaheri’s team to investigate the anticancer properties of carnosol on the TNBC cell
line, MDA-MB-231

[50]

. They have started their investigation by examining the

viability of MDA-MB-231 cells upon the treatment with different concentrations (25,
50, and 100 μM) of carnosol for 24 h and 48 h, and results showed that carnosol
exhibited antiproliferative activity in concentration- and time-dependent manner.
Next, they inspected whether carnosol reduced viability via the induction of the
apoptosis pathway. Annexin V staining (detect apoptotic cells by binding to
phosphatidylserine), activation of intrinsic apoptosis (cleaved PARP and caspase 3),
and extrinsic apoptosis (caspase 8 and 9) pathways were detected in the high
concentration conditions only (50 and 100 μM) at 24 h. Moreover, carnosol had
modulated the expression of Bcl-2/Bax and induced mitochondrial membrane
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potential depolarization, which is associated with the activation of apoptosis observed
in the MDA-MB-231 cells [50].

1.3.3.2.2 Carnosol Induces Autophagy
Autophagy is another mechanism that serves to maintain cellular homeostasis via
dragging damaged or unwanted cellular components to the lysosome, either to get rid
of it or recycle it and results in promoting cellular survival. In this way, cancer cells
can use autophagy to prevent the accumulation of cellular damages caused by
chemotherapeutics, promoting temporal survival and developing chemoresistance [76].
Several pieces of evidence have indicated that autophagy is involved in cancer cells’
adaptation to chemotherapy

[77,78]

. This suggests that when the tumor is undergoing

chemotherapy, most often activate autophagy as a cytoprotective mechanism to
survive the effects of anticancer drugs, which, sequentially, may drive
chemoresistance. Contrary to its cytoprotective role, autophagy is also known to cause
cell death stimulated by excessive cellular stress, for that it is called; type II
programmed cell death

[79]

. More importantly, cell death mediated by autophagy can

involve the stimulation of apoptosis

[80,8]

. In contrast, inhibiting autophagy has been

detected to reduce apoptosis in some tumors

[82]

. In this regard, both cell death

mechanisms apoptosis and autophagy may crisscross with each other and share
common actions to derive cellular death response.

This controversial role of autophagy derives Al Dhaheri and coworkers to investigate
the existence of autophagy in TNBC upon the treatment with carnosol. In the begining,
they observed under light and electron microscopy the presence of cytoplasmic
vacuolation is present, which might be associated with autophagy induction. To further
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confirm the presence of autophagy, they assessed first the conversion of LC3I
(cytosolic form) into a lipidized LC3II (autophagosome membrane-bound form) which
is one of the characteristics of autophagy initiation has. Carnosol was found to induce
the accumulation of LC3II in a concentration-dependent manner. Another widely
known autophagy marker was evaluated is p62 (SQSTM1), a ubiquitin-binding protein
whose level decreases when autophagy flux increases. At a lower concentration of
carnosol (25 μM), there was a slight increase in p62 (SQSTM1) expression;
nonetheless, at higher concentrations (50 and 100 μM), where massive autophagy
exists, p62 (SQSTM1) decreases. Next, they assessed the expression of Beclin-1
(responsible for autophagosome formation, a step in forming autophagic vacuoles).
Beclin-1 remained unchanged in response to carnosol, hence suggesting that carnosol
induces autophagy in Beclin-1-independent mode. To confirm that Beclin-1 is not
needed for autophagy initiation, knocking down Beclin-1 using siRNA was done, they
found that Beclin1-1 siRNA did not inhibit LC3II accumulation autophagy was
successfully induced by carnosol [50].

This study showed that both cell death mechanisms, apoptosis, and autophagy, coexist
in MDA-MB-231 cells upon the treatment with carnosol. Apoptosis was observed at
higher concentrations of carnosol (50 and 100 μM), while autophagy was observed at
a lower (non-cytotoxic) concentration (25 μM) and higher concentration as well. This
indicates that MDA-MB-231 is treated with carnosol, firstly, it undergoes autophagy,
and after more prolonged exposure to carnosol, which causes excessive cellular
damage, this leads the cells to progress to apoptosis. To endorse this, a time-course
experiment with carnosol treatment (100 μM) was used to check the expression of
PARP (apoptosis marker) and LC3II (autophagy marker), LC3II was provoked at 3 h,
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while cleaved PARP was started at 24 h [50]. This result clearly indicates that autophagy
preceded apoptosis in carnosol-treated triple-negative MDA-MB-231 cells.

1.3.3.3 Anticancer Effects of Carnosol through CYPs Enzyme Inhibition
In 2013, a study by Rodriguez and Potter evaluated the status of cytochrome P450-1A1
(CYP1A1) in estrogen receptor-positive (MCF-7) and triple negative (MDA-MB-231)
breast cancer cell lines [62]. CYP1A1 is an enzyme that belongs to the cytochrome P450
superfamily and gets induced and expressed by the aryl hydrocarbon receptor (AhR),
a transcription factor that gets activated via the binding to cytosolic ligands [84]. The
enzyme CYP1A1 involves catalysis of several reactions in cholesterol, drugs, steroids,
and metabolizing various procarcinogens to be active human carcinogens

[85]

. In

addition to that, studies revealed that around 90% of breast cancer patients expressed
CYP1A1 [86]. This raises the interest of CYP1A1 in breast cancer, hence exploring its
activity in breast cancer progression and discovering its impacts on therapeutics will
assist in developing and improving treatment strategies. Thus, Rodriguez and Potter
decided to determine CYP1A1 biological properties and its role in the signal
transduction of breast cancer cells, including triple-negative [62]. Firstly, to understand
the biological role of CYP1A1 in both breast cancer cell lines MDA-MB-231 and
MCF-7, they utilized siRNA to knock down CYP1A1 mRNA and protein. CYP1A1
silencing results in the impairment of cellular proliferation and survival, blocks the
cell cycle at G0/G1, increases apoptosis, inhibits the ERK1/2 and AKT, and induces
the AMPK pathway. After that, they sought to use carnosol as a pharmacological
approach to reduce CYP1A1. Previous studies have shown that carnosol inhibits
AhR and reduces CYP1A1 expression in premalignant tongue and prostate cancer
[70,83]

. Consistent with that, pharmacologic reduction of CYP1A1 levels by carnosol
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also reduces proliferation, partly through the activation of the AMPK pathway
[61]

. Together these results suggest decreasing CYP1A1 levels using RNA silencing

or carnosol might be a potential new method for triple-negative and estrogenpositive breast cancer treatment.
1.3.3.4 The Synergetic Anticancer Effects of Carnosol in Combination Therapy
Despite the increasing interest in the anticancer effect of carnosol during cancer
initiation and progression

[56,84–90]

, few studies have proved the efficacy of using

diterpenoids in monotherapy or when combined with other phytochemicals or
chemotherapeutic agents [91–93]. To achieve this, Vergara and coworkers (2014) studied
the antitumor activity of the dietary diterpene carnosol alone and in combination with
other phytochemicals or with commonly used chemotherapeutic drugs using several
human cancer cell lines including TNBC (HBL-100, MDA-231, and MDA-435) [62].
The results of the MTT assay revealed that carnosol alone decreases the cellular
viability of TNBC and other cell lines in a dose- and time-dependent manner. Several
researchers have demonstrated that a combination of phytochemicals can be more
efficient in cancer prevention and treatment than single compounds

[94,95]

. For this

reason, Vergara et al. treated the TNBC cell line (MDA-MB-231) with a combination
therapy consisting of carnosol (50 μM) and curcumin (70 μM) for 4 hours and assessed
their potential synergetic effects using western blotting. Combination therapy reduces
Bcl-2, cyclin D1, and survivin while increasing p27 more efficiently than
monotreatment. These results showed promising synergetic potential by reducing
vitality, inducing apoptosis, and cause cell cycle blockade

[62]

. Overall, this study

provided promising evidence on the synergetic anticancer effects of using carnosol in
combination therapy to treat TNBC.
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1.3.3.5 Carnosol Stimulate ROS Production
A study by Wong and collaborators showed that ROS (reactive oxygen species) leads
to the activation of apoptosis and beclin-1-independent autophagy in many cancer cell
lines including the breast cancer MDA-MB-231 cells. In addition to that, ROS was
found to activate ERK1/2

[96]

. The ROS generation was evaluated with different

concentrations of carnosol present using DCFDA fluorescence stain. ROS was found
to be accumulated in carnosol treated MDA-MB-231 cells in a time- and
concentration-dependent. Moreover, phosph-ERK1/2 and ∂H2AX (DNA damage
marker) expression were elevated upon carnosol treatment
literature showed that ROS trigger autophagy and apoptosis

[50]

. Evidence in the

[97]

. To investigate this,

they treated MDA-MB-231 cells with carnosol and tiron (ROS scavenger), a decrease
in DNA damage, LC3II accumulation, and cleaved PARP were observed

[50]

. This

result demonstrates that carnosol exerts its anti-breast cancer effect through a ROSdependent mechanism. Lastly, they found that carnosol also inhibits colony growth
formation in TNBC cells.
1.4 Targeted Pathways in TNBC Progression in This Study
1.4.1 Cancer Migration, Invasion and Metastasis
Cancer metastasis is a process in which cancer cells spread to tissues and organs
beyond where the primary tumor originated and forming new tumors (secondary and
tertiary foci). Metastasis is the hallmark or cancer that being the key cause of cancer
therapy failure and responsible for the greatest number of cancer mortality, and yet, it
remains poorly understood

[98]

. Triple-negative breast tumors are an invasive type of

cancer and usually characterized with poor prognosis and survival, relapse quickly,
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and high incidence of metastasis. Treatment options for TNBC have been limited due
to the absence of targetable hormone receptors and HER2 expression

[99]

. Although

TNBC has a high response rate to chemotherapy at early treatment stages, it tends to
relapse, and metastatic tumor develop. Once metastasis occurs, TNBC is incurable
with an overall survival of only 10–13 months

[100]

. Hence, improving our

understanding on the molecular mechanisms of TNBC metastasis might enhance the
clinical management of this disease.
Metastasis is a complicated event that include a series of multiple steps. The metastasis
cascade starts with detachment and migration of metastatic cells from the primary
tumor, then, invading the basement membrane (BM) and extracellular matrix (ECM)
surrounding the primary tumor (detachment, migration, and invasion). After that,
invading the BM of the endothelium nearby blood and lymphatic vessels, by then,
metastatic cells will intravasate the lymphatic system (intravasation) and will go
through the circulation. Once metastatic cells reach the capillary endothelium of
targeted organs, it adheres to the endothelium and invades the endothelial cell layer
and the surrounding BM to extravasate to the targeted secondary tissue or organ
(extravasation). Finally, metastatic cancer cells colonize and build blood vessels to
enrich themselves (angiogenesis) and secondary tumor start growing [101–103].
1.4.1.1 The Role of MMP-2 and MMP-9 in Cancer Metastasis
The regulation of metastasis includes various signaling pathways and is affected by
the surrounding ECM components. One of the important steps in cancer metastasis is
invasion, which involves the disassembly of extracellular matrix and its constituents
by special enzymes, like matrix metalloproteinases (MMPs) [104]. MMPs are a family
of zinc-dependent endoproteinases

[105]

and are known to play a key role in multiple
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physiological processes, such as embryonic development, human reproduction and
tissue remodeling, in addition to invasion and metastasis of cancer

[106,107]

. In tumor

cells, the increased expression and activity of MMPs result in the degradation of ECM
and BM, allowing tumor cells to invade other tissues and metastasis to distant organs
[108]

. Additionally, MMPs can modify cell adhesion molecules, and activate cytokines

by proteolytic cleavage, resulting in the induction of epithelial-mesenchymal transition
(EMT), a phenotypic alteration to enhance cell motility

[109–111]

. They also release

soluble factors from the primary tumor site into the circulation, supporting establishing
a metastatic niche in distant organs, subsequently helping tumor cells colonize

[109]

.

Interestingly, MMPs not only produced by tumor cells, but also by stromal cell in the
tumor microenvironment, as a consequent response to reciprocal paracrine interactions
[112]

. Several studies have reported an elevated MMPs protein expression in almost all

cancer types and associated with poor prognosis [113].

There are several subtypes of MMPs that differ structurally and functionally within the
MMPs family, among them the gelatinase MMP-2 and MMP-9, which are responsible
for degrading gelatin, type IV and V collagens in BM and ECM through their
proteolytic activity

[114]

. Some studies have revealed a link between the increased

protein expression of MMP-2 and MMP-9 and the invasive capability of breast cancers
has compared to a normal breast epithelium. In particular, breast cancer cells
undergoing EMT have high expression of both MMP-2 and MMP-9

[115,116]

have been implicated in breast cancer development and progression

, which

[117,118]

. In

addition, a study by Li et al. showed that TNBC cells (MDA-MB-231) had a
significant increase in MMP-2 and MMP-9 mRNA and protein expression compared
to human normal breast cell line (HS578Bst). These results correlate with the increase
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in lymph node metastasis, tumor staging and poor prognosis [119]. Another report also
showed that highly expressed MMP-2 and MMP-9 is also increasing the poor
prognosis of triple-negative, with shorter overall survival and shorter progression-free
survival

[120]

. Confirming previous studies, Sullu et al, have indicated that the high

expression of MMP-9 is associated with poor prognostic factors, like tumor grade,
distant metastasis [121]. Therefore, understanding MMP-9 and MMP-2 expression and
activity regulation can help identify targeted therapies and guide TNBC prognosis.

1.4.1.2 STAT3 Regulates the Expression of MMP-2 and MMP-9 in Cancer
Metastasis
It has been reported that protein expression involved in the pathways of invasion
(MMP-2 and MMP-9), EMT (twist and vimentin), angiogenesis (VEGF and HIF⍺),
and proliferation and survival (cyclin D1, c-Myc, Bcl2, p53) are downstream of
STAT3 transcriptional regulation. STAT3 (signal transducer and activator of
transcription 3) is a member of the STAT family, and it is found constitutively active
in all breast cancer subtypes, yet it is found highly expressed in TNBC and associated
with its invasiveness

[122–124]

. The activation of STAT3 happens through the

phosphorylation of its serine and tyrosine residues via signaling from upstream
regulators such as cytokines and growth factors for receptor tyrosine kinases nonreceptor tyrosine kinases, serine kinases and Gα‐interacting vesicle‐associated protein
(GIV/Girdin)/guanine nucleotide exchange factor (GEF)

[125,126]

. Phosphorylated

STAT3 induces homodimerization between two STAT3 molecules, then, formed
homodimer translocate to the nucleus to bind to the consensus promoter sequence of
its downstream target genes to initiate transcription [125].
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Ma et al. have investigated the inhibition of STAT3 phosphorylation in breast cancer,
which result in reduction of the expression of MMP-9, MMP-2 in addition to
vasodilator-stimulated phosphoprotein (VASP) [127]. Additionally, Dai et al. revealed
that posttranscriptional modification of STAT3 promote its phosphorylation which
results in its activation, this ultimately cause an increase in MMP2 and MMP9 in the
triple-negative MDA-MB-231[128]. The inhibition of the upstream regulator enzyme of
STAT3 was found to reduce cell viability, migration, and invasion stimulated by
MMP-2 and MMP-9

[128]

. Further investigation of STAT3 stimulated MMPs

expression in metastasis is crucial to find targeted therapies or enhance current
treatment for metastatic TNBCs.

It is pertinent to state that the primary reason of death from breast cancer has been
attributed to the distant metastasis. Oleandrin and odosroside are phytochemicals
extracted from Nerium oleander. A study by Pongrakhananon has shown reduction in
death among breast cancer patients who had treated with these compounds

[129]

.

Another study confirmed that Oleandrin inhibits the activity of MMP9 and octamer
binding transcription factor 3/4 (OCT3/4) through suppression of STAT3 at 50 and
100 nM used concentrations, respectively

[130]

. Moreover, Suh et al. revealed that

treating breast cancer cell lines (MDA-MB-231 and MCF7) with resveratrol (a
stilbenoid polyphenol found in grape skins and peanuts) was able to inhibit
proliferation, migration, and invasion. In particular, resveratrol have found to
downregulate the gene expression of Cyclin D1, c-Myc, MMP-9, MMP-2 and the
protein expression of SOX2 as well as inhibit the activation of Akt and STAT3 in
breast cancer cells [131].
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The polyphenol carnosol have been experimented for its anticancer activity, and it has
been found to suppress proliferation and migration in pancreatic cancer
cancer

[133]

and skin cancer

[133]

[132]

, brain

. These studies showed the therapeutic potential of

using carnosol in cancer therapy, which make a promising target to treat the metastatic
TNBC.

1.4.2 ROS Production Induces ER Stress and UPR in Cancer
The endoplasmic reticulum (ER) is a multifunctional organelle mainly responsible for
the proteins folding and trafficking and maintaining other cellular functions. Changes
in the protein-folding environment have led to the accumulation of unfolded or
misfolded proteins in the ER lumen, profoundly affecting several cellular processes
and causes ER stress

[134]

. The ER stress induces a collection of adaptive signaling

pathways called an unfolded protein response (UPR) that involves the restoration of
an efficient protein-folding environment and resolved misfolded protein

[135]

.

However, if the ER stress is too severe to be rescued, UPR will trigger autophagy or
apoptosis [136,137].

UPR is a highly regulated cascades system, and it involves three key sensors located
on the ER membrane; protein kinase R-like ER kinase (PERK), transcription factor 6
(ATF6), and inositol requiring enzyme 1α (IRE1α)

[135]

. PERK is a kinase; upon ER

stress, it phosphorylates the alpha subunit of the eukaryotic translation initiation factor2 (eIF2α). Then, phosphorylated eIF2α rapidly attenuates protein translation and
decreases the overload of proteins in the ER lumen. This action also promotes the
expression of the UPR transcription factor ATF4, which triggers apoptosis through
activating pro-apoptotic transcription factor CCAAT/enhancer-binding protein-
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homologous protein (CHOP), which leads to apoptosis or induce cell cycle arrest
[138,139]

. CHOP can be induced by both cascades PERK/ATF4 and ATF6

[140–142]

.

Another UPR sensor is ATF6; under ER stress, it is transported to the Golgi apparatus
and cleaved by specific proteases, which release its cytosolic fragment that function as
a transcription factor. Activate ATF6 is known to regulate the expression of genes
involved in the degradation of misfolded proteins [137]. The last UPR sensor is IRE1, a
kinase and an endoribonuclease (RNase); upon its activation, it catalyzes the splicing
of X-box binding protein 1(XBP1) mRNA. XBP1 is a transcription activator of
essentials genes known to control protein folding, trafficking, phospho-lipid
biosynthesis, and ER membrane expansion [143,144].

Accumulated evidence reported that UPR signaling cascades are activated in response
to reactive oxygen species (ROS) accumulation or oxidative triggers

[145]

. Abnormal

increases in ROS cause damage to cellular lipids, proteins, and DNA, resulting in
irreversible oxidative damage, which ultimately leads to cell death and different
pathological condition such as neurogenerative disease and cardiovascular disease
[146]

. On the other hand, several studies have suggested the beneficial effects of ROS

generation on chemotherapy-induced cell death in cancer cells

[147–149]

. For example,

bortezomib [150], apatinib (a TKI) [151], doxorubicin, inostamycin, vinblastin, xanthine
oxidase–conjugated polymer, and camptothecin are chemotherapeutic agents that
observed to induce apoptosis by increasing ROS production [152,153]. Since some tumors
are more sensitive to ROS than normal cells [149], therefore, ROS generation could be
an effective approach for killing tumor cells selectively without causing significant
toxicity to normal cells

[154,155]

. Finding a new drug that stimulates ROS production
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and ultimately leads to UPR activation is considered a goal for new effective
therapeutic approaches in cancer treatment.

1.4.2.1 The role of P38 in Regulating Cell death Upon ROS-induced ER Stress in
Cancer
Over 33 years back, Ray and Sturgill have identified and characterized a new
serine/threonine kinase signaling pathways family called MAPK (mitogen-activated
protein kinase)

[156,157]

. MAPK signaling plays a crucial role in regulating various

biological processes via different cellular mechanisms. MAPK signaling pathways
getting activated via extracellular stimuli, such as oxidative stress, Gi-coupled receptor
(GPCR), ultraviolet irradiation and genotoxic agents, inflammation, and other
stimulants. Once activated or deactivated, MAPK will exert extracellular stimuli on a
wide range of biological and cellular responses. These biological processes involved;
cellular growth, proliferation, differentiation, migration, senescence, cell death [158,159]
and others. MAPK is activated by dual phosphorylation on Thr and Tyr residues
located in the kinase activation loop (T-loop)

[160]

. Their phosphorylation is done

through a triple kinase module comprising a MAPK kinase kinase (MKKK) that
phosphorylates and activates a MAPK kinase (MKK) which can trigger the terminal
MAPK

[161]

. On the other hand, the inactivation of MAPK is through

dephosphorylating its Thr and Tyr residues mediated by phosphatase [162]. In general,
the cellular outcomes of MAPK cascades are dependent on different factors such as
subcellular localization, amount and duration of MAPK activation, and the crosstalk
with other signaling pathways inputs [163].

MAPK cascades are ubiquitous signal transduction pathways that regulate all aspects
of life, and their alteration leads to human cancers and other diseases. There are three
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prominent classical MAPK families in mammals: p38 kinase, C-Jun N-terminal kinase
(JNK), and extracellular-regulated kinase (ERK1/2) [164]. MAPK is known to be highly
involved in oncogenesis, tumor progression, and drug resistance [165]. P38 is a stressactivated MAPK, has pleiotropic effects on cancer, in which it has variable effects in
different tumors. However, its outcomes are significant for the sensitivity to drug
therapy [166]. For example, activated p38α was reported to induce cell cycle arrest and
senescence

. Also, p38α can suppress breast, colon, liver, and lung tumor

[167–171]

progression through ROS production and, consequently, mediate pro-apoptotic signals
in these tumors [172]. On the other hand, p38 enhances lung metastasis of breast cancer
through upregulating the expression of pro-metastatic genes [173]. Moreover, p38 was
reported to enhance epithelial-to-mesenchymal transition and metastasis in other
tumors [174,175]. Therefore, targeting the MAPK p38 in cancer therapy might have twoedged sword impacts.

1.4.3 The Role of Post-translational Modifications in Cancer Gene Expression
Eukaryotic DNA is tightly wrapped around a cluster of eight proteins named core
histones to form the chromatin’s basic units, which is nucleosomes. Post-translational
modifications of histones, such as methylation, phosphorylation, ubiquitylation and
acetylation, are essential components of the epigenome

[176]

. Acetylation is classified

among the most abundant modifications involved in various key cellular processes
such as cellular proliferation
[178,179]

[177]

, cell-cycle progression, differentiation, apoptosis

, dosage compensation, hormonal signaling

[180]

, gene transcription, DNA

damage repair, protein folding, autophagy and metabolism [181].
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Acetylation of histones is a very well controlled process and it is one of the main
epigenetic modifications that play a role in chromatin remodeling and dynamics with
an impact on gene expression and transcriptional activities, and overall cellular
homeostasis [182]. Histones or non-histones proteins acetylation being regulated by two
classes of enzyme family members, working in an opposite mode: histone
acetyltransferases (HATs) and histone deacetylases (HDACs)

[183,184]

. The dynamic

and reversible acetylation of histone and non-histone proteins is a major epigenetic
regulatory mechanism of genes transcription and deregulation of this process have
been implicated in a wide variety of human diseases; for instance, developmental
disorders

[185–190]

breast cancer

, leukemia

[195]

[191,192]

, pancreatic cancer

[193]

, prostate cancer

[194]

and

, inflammation and immunity, and neurological and metabolic

diseases such as diabetes

[196,197]

. Thus, proteins involved in the regulation of

acetylation status considered as an attractive therapeutic target.

1.4.3.1 The Role of P300 in Cancer Progression
Most of the canonical mammalian HATs are classified into three major families that
have been well characterized: the GNAT, the MYST, and the P300/CBP families. The
HATs p300/CBP were formerly discovered as E1A oncoprotein binding partners and
cyclic AMP effectors, and then have addressed as global transcriptional coactivator
[198]

. In 1996, p300/CBP was described to possess HAT activity [199,200] and as a lysine

acetyl-transferase is involved in regulating a wide range of biological processes

[201]

.

Recent studies indicate that the HAT activity of p300/CBP have been associated with
tumor development and progeression [202–205]. Deregulated HAT activity is particularly
linked to cancer formation and progression [206,207], which is observed in several solid
tumors, including prostate

[201,208]

, colon

[209,210]

and breast

[211,212]

cancers.
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Additionally, it have been shown that a functional p300 decrease the sensitivity to
chemotherapy in estrogen-positive breast cancer, high recurrence and poor prognosis,
mediate inflammation and tumor progression in triple negative breast cancer as well
[213–216]

. Therefore, HATs and HDACs are potential drug targets, and the restoration or

modification of their activity could be beneficial for both the management and
treatment of cancer [206,207].

Although there are increasing body of evidences suggests that p300 may be an
important player in cancer [217]. However, its precise role is not clear and may depend
on the physiologic background of the tumor [201]. Interestingly, evidence indicates that
p300 can function both as a tumor suppressor and as an oncoprotein in cancer [217]. In
fact, in invasive breast cancer, the high expression of p300 correlates with recurrence
and poor patients’ prognosis

[216,218]

. Moreover, p300 was reported to be involved in

breast cancer progression by promoting cellular invasion and cellular survival

[219]

.

Additionally, a functional p300 has been revealed to in association with a decrease in
the sensitivity to chemotherapy in estrogen-positive breast cancer, high recurrence and
poor prognosis, mediate inflammation and tumor progression in triple negative breast
cancer as well

[213–216]

. Hence, targeting p300 in invasive breast cancer may be a

promising approach for developing novel anticancer therapy.

Although studies on HDAC inhibitors have discovered highly potent compounds with
rich clinical impact in cancer, the identification of HAT inhibitors has faced more
challenges, and only a few potent ones have been identified [220,221]. These potent HAT
inhibitors have been tested for their therapeutic potential in cancer [217,222,223] and other
diseases [224–226].
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PCAF (p300/CBP-associated factor), another histone acetyltransferase, and a
component of several protein complexes was shown to play distinct roles in cancer,
such as tumor suppressors, oncogenes, and transcription factors that control cell
differentiation and cell cycle [227]. For instance, PCAF can acetylate NF-κB in response
to inflammation and immunity [228], or it can acetylate p53 in response to DNA damage
leading to cell cycle arrest [229]. Also, PCAF has been reported to function as a tumor
repressor by promoting apoptosis in hepatocellular carcinoma [230] and inhibit the cell
cycle in gastric cancer cells

[231]

. On the other hand, PCAF was found to promote

tumorigenicity in lung adenocarcinoma via acetylating EZH2

[232]

and enhances

cellular proliferation of glioblastoma via Akt1 acetylation [233].

Recent investigations suggest that several dietary compounds have modified cancer
risk epigenetically. Since post-translational modifications have been associated with
the development and progression of some cancers, alteration of these events by dietary
constituents provides a potential mechanism for their cancer-protective effects

[220]

.

Various phytochemicals have been identified as modulators of the acetylation state of
histones or affect the activities of HATs and/or HDACs [234]. Curcumin [235], anacardic
acid

[236]

, garcinol

[237]

, epigallocatchechin 3-gallate

[238]

, epigallocatechin-3-gallate

(EGCG) [238], garcinol and isogarcinol [42,43] , veratric acid-derived [239] and plumbagin
[240]

have been showed to possess specific HAT inhibitor activity. Among these,

curcumin was found to be the only known p300-specific natural inhibitor, both in vitro
and in vivo, which is also cell-permeable

[235,241]

. Interestingly, curcumin’s specific

binding on p300/CBP led to a conformational change resulting in a decrease in the
binding efficiency of histones H3, H4, and acetyl CoA [241].
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Several screening researchers have identified natural product derivatives of potency as
p300 HAT inhibitors; however, their selectivity and a detailed inhibition mechanism
remain fully characterized. Carnosol is also a kind of polyphenol currently receiving
increasing attention for its various health-promoting properties, including anti-breast
cancer. Therefore, further investigation of the molecular mechanism of carnosol action
on TNBCs, particularly on HATs activity, might reveal promising effects that result in
enhancing current treatment.
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Chapter 2: Materials and Methods
2.1 Cell Culture and Chemicals
Human breast cancer cell lines, MDA-MB-231, MCF-7, T47D and Hs578T, were
purchased from Cell Line Service (CLS)-GmbH and ATCC-USA. MDA-MB-231,
Hs578T, and MCF-7 cell lines were cultured in DMEM medium and T47D in RPMI
medium, the medium was supplemented with 10% fetal bovine serum (FBS) and 1%
(100 μ/ml) penicillin/streptomycin, and the culturing condition was maintained at
37ºC, 5% CO2 and 95% humidity. The reference of used cell lines, medium and its
supplements, carnosol compound, apoptosis, autophagy and proteosome inhibitors,
ROS scavenger, recombinant proteins, antibodies, and all other used reagents
throughout the study are listed in the Appendix.
2.2 Wound Healing Assay
The migration capability of MDA-MB-231 and Hs578T cell lines was evaluated using
Wound Healing Assay. Cells were cultured in 6-well plates overnight until it reaches
confluency. The next day, a number of three wound lines were made in each well
throughout the cells confluent monolayer using a sterile plastic pipette tip, 10 μl. Then,
the cells were washed twice with PBS carefully, and cells were incubated at 37°C in a
freshly prepared DMEM medium supplemented with FBS and antibiotic, and different
concentration of carnosol were added accordingly. The wounds width was examined,
and pictures were captured using inverted microscope at 100X magnification (Nikon
Ti-U, Nikon) at indicated time points, 0 h and 5 h. The migration distance (d) of the
cells was calculated as the following: d = (size of the wound at t = 0 h - size of the
wound at t = 5 h).
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2.3 Measurement of Cellular Viability
Cells were cultured in 12 well plates in a density of 40,000 cells/well and incubated
overnight. The day after, cells were treated according to the plan and incubated for 24
h. Next, viable cells were collected and treated with the Muse Count and Viability Kit
(Cat# MCH100102, Millipore, Hayward, CA, USA) reagents according to the
manufacturer's protocols. The assessment of the number of viable cells was carried out
using by Muse™ Cell Analyzer (Millipore).

Other assays were used to measure the cellular viability are through Cell Cytotoxicity
Assay Kit (Cat# ab112118, Abcam, UK) and MTT Assay Kit (Cat# ab211091, Abcam,
UK). Cells were seeded in 96-well plates at a density of 6,000 cells per well. After
24 h of culture, cells were treated with 0.2% (DMSO) or the indicated concentrations
of carnosol and incubated for 24 h. After that, Kits reagents were applied according to
the manufacturer’s guideline. Viability was measured via monitoring the changes in
the absorbance at 570 nm and 605 nm in a microplate reader, Platos R 496. The
percentage of viability was calculated as following: % cell viability = 100 ×
(absorbance of treated sample / absorbance of control sample)

2.4 Matrigel Invasion Assays
BD Matrigel Invasion Chamber (Cat# 354480, 8 μm pore size; BD Biosciences,
Bedfrord, MA, USA) was used to assess the invasiveness of MDA-MB-231 cells.
According to manufacturer's instructions, in each well of the 24-well chamber plate,
5000 cells were placed in 0.5 mL of medium containing vehicle 0.2% (DMSO) or the
indicated concentrations of carnosol, then cells were seeded into the upper chambers
of the system; while the bottom wells in the system were filled with DMEM
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supplemented with 10% FBS as a chemoattractant and then incubated at 37°C for 24 h.
The cells that did not penetrate the matrigel were removed from the upper surface of
the filter with a cotton swab. Cells that have migrated throughout the matrigel to the
lower surface of the chamber were fixed with 4% formaldehyde and stained with
DAPI. Fluorescence from DAPI stain was revealed using a filter with excitation
wavelength of 330–380 nm and barrier filter of 400 nm. DAPI-stained nuclei were
counted in 10 random fields per well using inverted fluorescence microscope at 200X
magnification (Nikon Ti-U, Nikon). For quantification, the assay was done in
duplicates and repeated three times.
2.5 Gelatin Zymography
MDA-MB-231 (2.5 ×106) cells were grown in serum-free medium containing vehicle
0.2% (DMSO) or the indicated concentrations of carnosol (25 and 50 μM) and
incubated for 24 h. After 24 h of incubation, the medium was collected from culture
and then concentrated. Total of 30 μg protein was resolved on non-reducing 10%
polyacrylamide gels containing 0.1% gelatin. After electrophoresis, the gels were
washed for 1 h in 2.5% (v/v) Triton X-100 to remove SDS and then incubated
overnight at 37°C in 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 0.5 mM ZnCl2, and 10
mM CaCl2 to allow proteolysis of the gelatin substrate. Coomassie brilliant blue R250 (Bio-Rad, CA, USA) staining was used with 0.5% to reveal gelatin-clear bands
corresponding to the MMPs activity. The density of the bands were measured using
ImageJ and band density was normalized to the non-specific band staining on the gel.
The results showed represent two independent experiments.
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2.6 Measurement of Matrix Metalloproteinase-9 by ELISA
Cells (0.5 ×106) were seeded in 6-well plates in the presence of vehicle (0.2% DMSO)
or carnosol (25 and 50 μM) for 24 h. Afterward, the conditioned medium was
collected, and the levels of secreted MMP-9 were assessed using MMP9 Human
ELISA kit (Abcam, Cambridge, UK) conferring to the manufacturer's protocol. The
proteins present in the conditioned media were concentrated using the Amicon Ultra0.5 protein purification and concentration column (Millipore). The protein levels of
MMP-9 were normalized to the total protein level in each sample. The assays were
performed three times in triplicates. Data are presented as mean values ± SEM.
2.7 Extraction of RNA and RT-PCR
MDA-MB-231 cells were treated with vehicle (0.2% DMSO) or carnosol (25 and 50
μM) for 24 h, then, the total RNA was extracted using TRIzol® Reagent (Cat#
15596026, Ambion, Life Technologies, Inc., USA) following the manufacturer’s
instructions. RNA expression of MMP-9 was determined by using the Qiagen OneStep
RT-PCR kit (Cat# 210212, QIAGEN OneStep RT-PCR Kit, Qiagen, USA) according
to manufacturer's guidelines. The amounts of RNA (500 ng) were equalized and used
as templates in each reaction. The sequences of used primers are listed in Table 2.
Table 2: The sequences of the used RNA primers
Primers sequences
MMP-9 Forward 5′- TTGACAGCGACAAGAAGTGG-3′
Reverse 5′- CCCTCAGTGAAGCGGTACAT-3′
MMP-2 Forward 5′-TCTCCTGACATTGACCTTGGC−3′
Reverse 5′-CAAGGTGCTGGCTGAGTAGATC−3′
GAPDH Forward 5′-GGCCTCCAAGGAGTAAGACC−3′
Reverse 5′- AGGGGTCTACATGGCAACTG-3′
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The PCR products were runed in 1.5% agarose gel and visualized via ethidium
bromide staining. The results were representative from three independent experiments
are shown.
2.8 Protein Extraction and Western Blotting Analysis
Cancer cell lines were cultured in a density of 2 ×106 cell per 100 mm tissue culture
dishe and incubated for 24 h. After that, treatment was applied for acquired times.
Once the incubation time was done, cells were washed twice with ice-cold 1X PBS,
scraped, collected by spinning down. The whole cell pellets were lysed in RIPA buffer
(Cat# 89901, Pierce, Thermo Scientific, USA) containing phosphatase inhibitor
cocktail; PhosSTOP EASTpack (Cat# 490684500, Roch, Germany) and cOmplete
ULTRA (Cat# 5892970001, Roch, Germany) followed by 30 min incubation on ice.
Later, cell lysates tubes were centrifuged at 14,000 rpm for 20 min at 4°C, and the
supernatants were collected. Total protein concentration was quantified through
Pierce™ BCA Protein Assay Kit (Cat# 23227, Thermo Scientific, USA) and the
background of the lysates were adjusted with lysis buffer. Aliquots of 20 μg of total
cell lysate were loaded and resolved onto 6–15% SDS-PAGE. The electrophoresis
running was on 1 X running buffer (30 g Tris-Base, Glycine 144 g and SDS 10 g), then
proteins were transferred from the gels to Immobilon-P Transfer Membranes (Cat#
IPVH00010, Millipore, Ireland) and wetted with 1X transfer Buffer (700 mL dH2O,
200 mL absolute methanol and 100 mL Running Buffer) for 1 h and 15 min at 100 V
at 4°C. Next, membranes were blocked for 1 h at room temperature with 5% non-fat
dry milk in 1X TBST (900 mL H2O, 100 mL TBS and 0.01% Tween 20), 10 X TBS
preparation as follow; Tis Base 24.2 g, NaCl 80 g and H2O 1 L. The membranes were
immunoblotted with specific primary antibodies prepared in blocking buffer overnight
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at 4°C and then with horseradish peroxidase-conjugated secondary antibodies against
rabbit or mouse or goat IgG. Immunoreactive protein bands were incubated with
Pierce™ ECL Western Blotting Substrate (Cat# 32209, Thermo Scientific, USA) and
SuperSignal™ West Femto Maximum Sensitivity Substrate (Cat# 34095, Thermo
Scientific, USA) and chemiluminescence was detected using the LiCOR C-DiGit blot.
2.9 In Vivo Study Using Chick Embryo to Assess Tumor Growth and Metastasis
of MDA-MB-231 Cells
The in vivo study was done using chick embryo to assess tumor growth and metastasis
upon carnosol treatment. This experiment was performed by INOVOTION (Société:
811310127), La Tronche-France and reconfirmed again in our lab (Pr. Iratni’s Lab) as
previously described [242]. INOVOTION used fertilized White Leghorn eggs, obtained
from the Société Française de Production Agricole (SFPA, St. Brieuc, France), and we
used fertilized egg brought from local farms, all eggs were incubated at 38°C with 60%
relative humidity for 10 days. As stated by the French legislation, no ethical approval
is required for scientific experimentations using oviparous embryos (decree n° 2013–
118, February 1, 2013; art. R-214–88). Animal studies were performed under animal
experimentation

permit

N°

381029

and

B3851610001

to

Jean

Viallet

(INOVOTION). According to the Animal Research Ethics Committee in United Arab
Emirates, ethical approval is needed (ERA-2018-5839, January 2019). Experiments
were done at UAE University in E3 building.

At day E10, the upper chorioallantoic membrane (CAM) was dropped by drilling a
small rounded hole (1 cm2) though the eggshell into the air sac and a window was
created in the eggshell above the CAM. Cultured MDA-MB-231-GFP were
trypsinized, then, neutralized with complete medium and suspended in serum free

36
DMEM. A 50 μl containing 1 x 106 MDA-MB-231-GFP cells was added onto the
upper CAM of each egg. Eggs were split randomly onto 4 groups of 15 eggs (to get
sufficient surviving embryos at the end of the experiments). One day later at E11,
tumors began to be visible. Tumors were treated every 2 days (E11, E13, E15, E17),
by dropping 100 μl of either carnosol (50 or 100 μM), colchicine (2 μM) as a positive
control, or vehicle (0.02 % DMSO) prepared in 1X PBS onto the tumor. At E19 the
upper portion of the CAM which include tumor was removed, transferred in 1X PBS
and the tumors were carefully cut away from normal CAM tissue and weighed. In
parallel, a 1 cm2 portion of the lower CAM was collected to calculate the number of
nodules, containing GFP-expressing cells. The fluorescent nodules were visualized in
situ using whole mounts of tissue fixed in 4% formaldehyde in 1X PBS and
compressed between a hollow glass slide and a thick coverslip. In order to count the
nodule, Leica Macrofluo fluorescent microscope equipped with GFP filter was used to
scan the previously prepared lower CAM samples. At the end, chick embryos were
sacrificed by decapitation.

2.10 Assessing Histone Acetyltransferase Activity Using Colorimetric Assay and
in Vitro Experiment
HAT activity was measured using the commercially available colorimetric HAT
activity assay kits such as Hitson Acetyltransferase Activity Assay Kit (Cat# ab65352,
Abcam, UK) and HAT Activity Assay Kit (Cat# ALX-850-326-KI01, Enzo, US).
Briefly, 50 µg of HeLa cell nuclear extract (Santa Cruz Biotechnology) was incubated,
with or without carnosol, in HAT assay buffer according to the manufacturer’s
instructions. Absorbance was measured at 450 nm using the microplate reader, Platos
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R 496. Experiments were done in triplicate and repeated in triplicates. Data are
represented as mean values ± SEM.

For the in vitro analysis 100 ng of recombinant HATs (p300, PCAF or GCN5) was
incubated in the presence of a HAT assay buffer (50 mM tris pH8.0, Glycerol 10%,
0.1 mM EDTA, 1 mM dithiotheithol, 1 mM PMSF), 400 nM trichostatin A, 20 µM
Acetyl-CoA in the presence of DMSO, as control, or carnosol for 1 h at 30°C. The
reaction was stopped by the addition of SDS-loading buffer (4X). HAT activity was
determined by Western Blotting using specific antibodies specific for acetylated
histones. Experiments were carried out in triplicate and repeated three times. Data are
represented as mean values ± SEM.

2.11 Statistical Data Analysis
The statistical analysis in the study was carried out through SPSS version 21 for PC
(IBM Corp.) and Microsoft Office Excel version 16.52 for Mac (21080801). Data were
reported as means ± SEM Differences between groups were analyzed using a Student's
I-test for paired or unpaired values. The significancy for all data was <0.05 for the Pvalue and taking into consideration that all experiments were repeated at least three
times and sometimes more.
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Chapter 3: Results and Discussion
3.1 Carnosol Inhibits Migration, Metastasis, and Tumor Growth of Breast
Cancer via a ROS-Dependent Proteasome Degradation of STAT3
3.1.1 Results
3.1.1.1 Carnosol Inhibits Migration of TNBC Cell Lines
TNBC is one of the aggressive diseases known for its high prevalence due to its
migration capacity and metastasis

[243]

. Cell migration capability is an initial and

critical step in the progression of cancer invasion and metastasis

[244]

. Therefore, the

effect of carnosol on the migratory capacity of TNBC cell lines, MDA-MB-231, and
Hs578T cells was analyzed using a wound-healing assay. The results showed that
carnosol significantly inhibited cellular migration of MDA-MB-231 (Figure 2A and
2B) and Hs578T cells (Figures 2D and 2E).

To rule out the possibility that the inhibition of cell migration is due to drug-induced
cell death, treated and non-treated (control) MDA-MB-231 cells were collected at the
end of the experiment by trypsinization, and the number of viable cells was quantified.
As is shown in Figure 2C, the number of viable cells did not decrease in carnosoltreated wells when compared to control.
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Figure 2: Carnosol hinders the migration of MDA-MB-231 and Hs578T cells.
(A) MDA-MB-231 cells were cultured till reaching confluency, a wound was introduced by scratching
with a pipette tip and the cells were incubated in DMEM without and with the indicated concentrations
of carnosol. The wound was examined with an inverted microscope 40X magnification and
photographed. (B) Quantitative assessment of the wound healing assay. Values represent the mean ±
SEM (n = 3) distance (arbitrary unit) that the cells have migrated 5 h post-treatment (*p < 0.05). (C)
Cellular viability of carnosol-treated MDA-MB-231 cells measured after 5 h post-treatment. Results
shows that no significant difference in number of viable cells between carnosol-treated and control cells.
(D) Hs578T cells were cultured till reaching confluency, a wound was introduced by scratching with a
pipette tip and the cells were incubated in DMEM without and with the indicated concentrations of
carnosol. The wound was examined with an inverted microscope 40X magnification and photographed.
(E) Quantitative assessment of the wound healing assay. Values represent the mean ± SEM (n = 2)
distance (arbitrary unit) that the cells have migrated 5 h post-treatment (**p<0.005).
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Figure 2: Carnosol hinders the migration of MDA-MB-231 and Hs578T cells
(Continued).
(A) MDA-MB-231 cells were cultured till reaching confluency, a wound was introduced by scratching
with a pipette tip and the cells were incubated in DMEM without and with the indicated concentrations
of carnosol. The wound was examined with an inverted microscope 40X magnification and
photographed. (B) Quantitative assessment of the wound healing assay. Values represent the mean ±
SEM (n = 3) distance (arbitrary unit) that the cells have migrated 5 h post-treatment (*p < 0.05). (C)
Cellular viability of carnosol-treated MDA-MB-231 cells measured after 5 h post-treatment. Results
shows that no significant difference in number of viable cells between carnosol-treated and control cells.
(D) Hs578T cells were cultured till reaching confluency, a wound was introduced by scratching with a
pipette tip and the cells were incubated in DMEM without and with the indicated concentrations of
carnosol. The wound was examined with an inverted microscope 40X magnification and photographed.
(E) Quantitative assessment of the wound healing assay. Values represent the mean ± SEM (n = 2)
distance (arbitrary unit) that the cells have migrated 5 h post-treatment (**p<0.005).
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3.1.1.2 Carnosol Decreases Invasive Capacity of MDA-MB-231 Cells
Cancer cells invasion is another critical step in metastasis that involves breaching
tissue barriers by cancer cells, which subsequently lead to the infiltration of these cells
into surrounding tissue

[245]

. One of the hallmarks of metastasis breast cancer is

increasing its invasion capacity

[246]

. Since carnosol had shown to suppress the

migration ability of TNBC cell lines, towered this, assessing the effect of carnosol on
the invasive potential of MDA-MB-231 cells using matrigel Invasion assay was done.
The assay revealed that the invasive ability of MDA-MB-231 was significantly
reduced by carnosol compared with the control cells (Figure 3A). Then, a
quantification of invaded MDA-MB-231 cells into the matrigel has shown that upon
carnosol treatment, the number of cells that invaded the matrigel coated membrane has
significantly reduced by 60%. Of note, LY294002, a drug used as a positive control,
strongly suppressed the invasion of MDA-MB-231 as well (Figure 3B). These results
indicate that carnosol has a significant suppressive capacity on the invasion of TNBC
cells.
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Figure 3: Carnosol constrains the invasion ability of MDA-MB-231 cells.
(A) MDA-MB-231 cells were incubated for 24 h with 25 µM of carnosol or without (a vehicle of 0.2%
DMSO) and LY294002 (20 µM). MDA-MB-231 Cells that were able to invade into the matrigel were
scored as described in Materials and Methods. (B) Quantitative analysis of invaded MDA-MB-231 into
the matrigel. Values represent means ± SEM, n = 3 (**p < 0.005 and ***p < 0.001).
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3.1.1.3 Carnosol Downregulates the Expression and the Activity of MMP-9 in
MDA-MB-231 Breast Cancer Cells
It is well known that MMP enzymes involve in the disassembly and degradation of
ECM and its constituents to facilitate cancer cell migration and invasion [104]. Several
studies have revealed a link between the increased protein expression of MMP-9 and
MMP-2 and the invasiveness of breast cancers

[115]

. Particularly, breast cancer cells

undergoing EMT have shown elevated expression of both MMP-9 and MMP-2

[116]

,

which have been implicated in breast cancer development and metastasis [118].
This draws us to analyze the effect of carnosol on the activity of MMP-9 and MMP-2
in breast cancer cells. Using gelatin zymography assay, carnosol significantly reduced
the activity of MMP-9 in a concentration-dependent manner in MDA-MB-231 cells
(Figure 4A). On the other hand, the activity of MMP-2 was not affected by carnosol
(Figure 4D). Next, to test whether carnosol inhibits breast cancer cell invasion by
affecting the expression of MMP-9, evaluating the expression level of MMP-9 in the
conditioned media was performed. As shown in Figure 4B, levels of secreted MMP-9
were significantly reduced in carnosol-treated MDA-MB-231 cells. Further, RT-PCR
analysis was achieved to evaluate the mRNA expression of MMP-9. The results
revealed that MMP-9 expression was down-regulated in carnosol-treated cells (Figure
4C). At the same time, the level of MMP-2 transcripts in carnosol-treated cells was not
affected in comparison to control cells (Figure 4E). Altogether, these data clearly
indicate that carnosol suppresses the expression and activity of MMP-9 activity.
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Figure 4: Carnosol downregulates MMP-9 activity and expression in MDA-MB-231
cells.
(A) The activity of MMP-9 in carnosol-treated MDA-MB-231 cells. Cells were treated with 25 µM
and 50 µM of carnosol for 24 h and then to measure the activity of MMP-9 samples were subjected to
gelatin zymography (B) Effects of carnosol on the secretion of MMP-9 in conditioned media. The levels
of secreted MMP-9 were evaluated using immunoassay kits as described in Materials and Methods.
Values represent the mean three samples ± SEM. (C) Effects of carnosol on the expression level of
MMP-9 mRNA. Cells were treated with vehicle (0.2% DMSO) or carnosol (25 µM and 50 µM) for 24
h and the subjected to RT-PCR to examine the mRNA level of MMP-9 transcript. GAPDH was used as
an internal control. Values represent the mean ± SEM (n = 3) (*p < 0.05). (D) Carnosol has no effect
on the expression and activity of MMP-2, a measurement of the activity of MMP-2 in carnosol-treated
MDA-MB-231 cells. Cells were treated with 25 µM and 50 µM carnosol for 24 hours and then subjected
to gelatin zymography, to measure the activity of MMP-2. (E) Effects of carnosol on the expression
level of MMP-2 mRNA. Cells were treated with vehicle (0.2% DMSO) or carnosol (25 µM and 50 µM)
for 24 h and subjected to RT-PCR to reveal the mRNA level of MM2-9 transcript. GAPDH was used
as an internal control.
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Figure 4: Carnosol downregulates MMP-9 activity and expression in MDA-MB-231
cells (Continued).
(A) The activity of MMP-9 in carnosol-treated MDA-MB-231 cells. Cells were treated with 25 µM
and 50 µM of carnosol for 24 h and then to measure the activity of MMP-9 samples were subjected to
gelatin zymography (B) Effects of carnosol on the secretion of MMP-9 in conditioned media. The levels
of secreted MMP-9 were evaluated using immunoassay kits as described in Materials and Methods.
Values represent the mean three samples ± SEM. (C) Effects of carnosol on the expression level of
MMP-9 mRNA. Cells were treated with vehicle (0.2% DMSO) or carnosol (25 µM and 50 µM) for 24
h and the subjected to RT-PCR to examine the mRNA level of MMP-9 transcript. GAPDH was used as
an internal control. Values represent the mean ± SEM (n = 3) (*p < 0.05). (D) Carnosol has no effect
on the expression and activity of MMP-2, a measurement of the activity of MMP-2 in carnosol-treated
MDA-MB-231 cells. Cells were treated with 25 µM and 50 µM carnosol for 24 hours and then subjected
to gelatin zymography, to measure the activity of MMP-2. (E) Effects of carnosol on the expression
level of MMP-2 mRNA. Cells were treated with vehicle (0.2% DMSO) or carnosol (25 µM and 50 µM)
for 24 h and subjected to RT-PCR to reveal the mRNA level of MM2-9 transcript. GAPDH was used
as an internal control.
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3.1.1.4 Carnosol Inhibits STAT3 Pathway by Downregulating Both Active and
Total STAT3 in Breast Cancer Cell Lines
STAT3 plays a crucial role in signaling pathways that promote cellular proliferation,
tumor angiogenesis, invasion, and migration. The active form of STAT3 is
constitutively and aberrantly activated in many types of cancers, including TNBC,
where it promotes tumorigenesis

[247]

. Thus, STAT3 is widely recognized as a

promising therapeutic target in cancer treatment.

Whether carnosol affects constitutively active STAT3 in MDA-MB-231 cells was
investigated. Toward this, cells were treated with carnosol (25, 50, and 100 μM) for
24 h. Carnosol was found to dramatically downregulated the level of phosphoSTAT3
in a concentration-dependent manner (Figure 5A, upper panel). Strikingly and
unexpectedly, cells treated with carnosol showed a marked reduction in the level of
total STAT3 (Figure 5A, lower panel). This finding prompted us to investigate whether
carnosol inhibits the STAT3 pathway in other breast cancer cell lines by
downregulating the level of total STAT3. In this direction, the level of total STAT3
was assessed in three other breast cancer cell lines (Hs578T, MCF-7, and T74D) cell
line. We found that carnosol also caused a marked decrease in the level of total STAT3
in these three cell lines as well (Figure 5B). Interestingly, and in agreement with
previous work

[248]

, we found that the expression of STAT3 was not affected in

HCT116 colorectal cancer cells after carnosol treatment (Figure 5C). In summary, our
data strongly suggest that carnosol inhibits the STAT3 pathway through a breast
cancer-specific mechanism.
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Figure 5: Carnosol inhibits STAT3 signaling pathway.
(A) Phospho-STAT3 and STAT3 protein were decreased in a concentration-dependent manner in
carnosol-treated MDA-MB-231 cells. Cells were treated with vehicle (0.2% DMSO) or indicated
concentrations of carnosol (25 µM, 50 µM and 100 µM) for 24 h, then whole-cell extracts were
subjected to Western Blotting analysis for the phosphorylated STAT3, total STAT3form and for β-actin
(loading control). (B) Carnosol downregulated the level of STAT3 protein in Hs578T, MCF-7, and
T47D breast cancer cell lines. Whole cell lysates from different breast cancer cell lines treated with the
indicated concentrations of carnosol were resolved on 8% SDS-PAGE and analyzed by Western blotting
for STAT3 protein. (C) Western blotting analysis of STAT3 protein level in HCT116 colorectal cancer
cells. Western blotting was implemented as described above.
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3.1.1.5 Carnosol Targets STAT3 to Proteasome-Mediated Degradation
To investigate the mechanism by which carnosol downregulates the level of total
STAT3 in breast cancer cells, the level of STAT3 protein in control and carnosoltreated MDA-MB-231 cells was examined by Western Blotting. Al Dhaheri et al. have
previously shown that carnosol triggered autophagy in breast cancer cells

[50]

.

Therefore, an assessment of whether STAT3 was degraded by autophagy was done.
The result showed that blockade of early-stage autophagy (autophagosome formation)
by 3-Methyladenine (3-MA) and late-stage autophagy (autophagolysosome formation)
by Chloroquine (CQ) did not restore the level of STAT3 protein (Figure 6A). This
suggests that the decrease of STAT3 proteins in response to carnosol is autophagyindependent.

To determine whether the proteasomal activity is involved in the carnosol-mediated
decrease of STAT3 protein, a pre-treatment for MDA-MB-231 cells with or without
the proteasome inhibitors carbobenzoxy-Leu-Leu-leucinal (MG-132) and bortezomib
was applied for 1 h and then with carnosol. As shown in Figure 6B, both inhibitors
efficiently restored STAT3 to a level comparable to that in control untreated cells. This
is a clear indication that carnosol targets STAT3 to proteasome degradation. In
addition, the results revealed that the restoration of STAT3 protein did not restore the
level of phosphorylated STAT3 (Figure 6B). Moreover, an examination of the effect
of proteasome inhibitor on STAT3 in another TNBC cell line, namely Hs578T was
carried out. As shown in Figure 6C, bortezomib restored the level of STAT3 protein.
Altogether, these data suggest that carnosol might exert its effect, at least partly,
through inhibition of the STAT3 signaling pathway by targeting STAT3 to proteasome
degradation in breast cancer.
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Figure 6: Proteasome-dependent degradation of STA3 protein in carnosol-treated
MDA-MB-231 and Hs578t cells.
(A) Inhibitors of autophagy didn’t restore STAT3 protein expression level. Western blot experiment of
STAT3 protein expression level in MDA-MB-231 cells pretreated with the autophagy inhibitors; CQ
and 3-MA. The cells firstly were pretreated with or without 3-MA (50 mM) and CQ (50 µM) for 1 h
and, followed by the addition of carnosol, and cells were further incubated for 24 h. (B) Inhibitors of
the proteasomes (MG-132 and Bortezomib) returned STAT3 protein to a level comparable to control
cells. MDA-MB-231 were pre-treated for 1 h with or without autophagy inhibitors; MG-132 (15 µM)
or Bortezomib (25 nM), followed by the addition of carnosol, and cells were further incubated for 24 h.
Whole cells lysate were resolved on 8% SDS-PAGE and examined by Western blotting for total STAT3
and phospho-STAT3 protein. (C) Carnosol induces proteasome-dependent degradation of STAT3 in
Hs578T. Inhibitors of the proteasomes (Bortezomib) rescued STAT3 protein from proteasome
degradation. Hs578T cells were pre-treated for 1 hour with or without Bortezomib (25 nM) before
treatment with carnosol at the indicated concentrations. Whole cells lysates were resolved on 8% SDSPAGE and evaluated by Western blot for STAT3 protein.
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3.1.1.6 Carnosol Promotes Proteasome Degradation of STAT3 Through a ROSDependent Mechanism
Another study besides Al Dhaheri et al. has previously shown that carnosol induced
ROS in breast [50] and colon [248] cancer cells. This prompted us to test whether ROS
contributes to STAT3 degradation. MDA-MB-231 cells were pre-treated with the ROS
scavenger, N-Acetyl Cysteine (NAC), for 1 h, and this was followed by treatment with
or without carnosol. As shown in Figure 7, blockade of ROS efficiently rescued
STAT3 from proteasomal degradation. This result demonstrates that carnosol targets
STAT3 to proteasome degradation through a ROS-dependent mechanism.

Figure 7: STAT3 degradation in a ROS-dependent manner.
MDA-MB-231 cells were pre-treated for 1 h with the ROS scavenger, NAC, then carnosol (50 and 100
µM) was added. Whole cells lysate was resolved on 8% SDS-PAGE and revealed by Western blotting
for STAT3 protein.

3.1.1.7 Carnosol Inhibits Tumor Growth and Metastasis of MDA-MB-231 Cells
Al Dhaheri et al. showed that carnosol significantly decreased the viability and colony
growth of MDA-MB-231 cells

[50]

. To further confirm these in vitro activities of

carnosol, in vivo experiment was carried out to investigate the effect of carnosol on
tumor growth using the chick embryo model. The highly invasive MDA-MB-231 cells
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were implanted on the chorioallantoic membrane (CAM), and then the formed tumors
were treated with vehicle (DMSO), colchicine (a positive control), or carnosol. At E
19, the tumors were recovered from the upper CAM and weighed each. The results
demonstrated that carnosol concentrations of 50 and 100 μM significantly inhibited
tumor growth by 65 and 75%, respectively, compared with the DMSO treatment
(Figures 8A, B). Colchicine treatment (2 μM) reduced tumor growth by 65%.
Furthermore, the ability of carnosol to inhibit metastasis was examined in vivo. To this
end, the number of nodules was counted in the lower CAM in DMSO-, colchicine- and
carnosol-treated tumors. An average of 6 nodules in the lower CAM of vehicle-treated
chick embryos were found, while an average of only 0.7 nodules was counted in
carnosol-treated embryos (Figure 8C). Taken together, these outcomes demonstrate
that carnosol strongly inhibits breast tumor growth and metastasis in vivo. Of note,
carnosol showed no cytotoxicity, as there was no difference in the number of surviving
embryos in control and carnosol-treated embryos.
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Figure 8: Antimetastatic and antitumor growth activity of carnosol on breast tumor in
chick embryo chorioallantoic membrane assay.
(A) MDA-MB-231 (1×106) cells were grafted on the CAM of 10-day chick embryo (E10). Every 48 h
Tumors were treated with carnosol (50 µM and 100 µM) or 0.2% DMSO (vehicle) or colchicine (2 µM)
as described in Materials and Methods. Later, tumors were collected and weighted at day 19 (E19). (B)
Weight measurements of tumors in vehicle-, colchicine- and carnosol-treated chick embryo. (C)
Antimetastatic effect of carnosol assessed by counting the nodules observed in the lower CAM of chick
embryo treated with vehicle, colchicine or indicated concentrations of carnosol. Columns represents
mean; bars represent SEM (***p< 0.001).
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Figure 8: Antimetastatic and antitumor growth activity of carnosol on breast tumor in
chick embryo chorioallantoic membrane assay (Continued).
(A) MDA-MB-231 (1×106) cells were grafted on the CAM of 10-day chick embryo (E10). Every 48 h
Tumors were treated with carnosol (50 µM and 100 µM) or 0.2% DMSO (vehicle) or colchicine (2 µM)
as described in Materials and Methods. Later, tumors were collected and weighted at day 19 (E19). (B)
Weight measurements of tumors in vehicle-, colchicine- and carnosol-treated chick embryo. (C)
Antimetastatic effect of carnosol assessed by counting the nodules observed in the lower CAM of chick
embryo treated with vehicle, colchicine or indicated concentrations of carnosol. Columns represents
mean; bars represent SEM (***p< 0.001).

3.1.2 Discussion
The aim of this part of the study (section 1) was to investigate the efficacy of carnosol
to inhibit tumor growth and metastasis of triple-negative breast cancer cell lines. The
results showed that carnosol markedly reduced the growth of the tumor-derived from
MDA-MB-231 cells and significantly inhibited invasion and metastasis both in
vitro and in vivo. Additionally, the results have demonstrated that carnosol exerts its
effect against breast cancer, at least partly, through downregulating the activity and the
expression of MMP-9, inhibiting the STAT3 signaling pathway through a ROSdependent proteasome degradation of STAT3 protein.
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Cancer metastasis is a complex process involving several steps, a critical one of which
is invasion, that involves proteolytic degradation of the ECM. It has been reported that
elevated levels of MMPs are linked to the aggressiveness of breast cancer and
metastatic potential [119,249,250]. Inhibiting the expression or activity of these proteases
is considered a potential therapeutic approach against breast cancer. Here, the results
in Section 1 showed that the anti-metastatic activity of carnosol involves suppressing
both the expression and activity of MMP-9. This implies that carnosol is expected to
reduce the degradation of the ECM.

Several signaling pathways, including STAT3, are known to regulate the expression
of various genes involved in the process of tumor migration and invasion. By virtue of
its ability to upregulate MMP-9, STAT3 appears to robustly enhance tumor migration
and invasion of MDA-MB-231 cells. Relevantly, a study by Kim and collaborators
showed that suppression of STAT3 phosphorylation by LYR71, a derivative of
trimeric resveratrol, was associated with an inhibition of MMP-9 in MDA-MB-231
cells

[251]

. This was further confirmed by Li et al.

Dees et al.

[253]

[252]

using pectolinarigenin and by

using pimozide agents to treat TNBC cell lines. Moreover, MMP-9

activation required the recruitment of STAT3 to MMP-9 promoter, and that LYR71
reduced MMP-9 transcripts by blocking STAT3 on the MMP-9 promoter [254].

Song et al. showed that juxtaposed STAT3/AP-1 element on the MMP-9 promoter
plays a crucial role in the manner of enhancer in the activation of the MMP-9 gene.
Indeed, a study reported that the functional cooperation of the STAT3 and AP-1
transcription factors is required for the transcription of the MMP-9 gene in breast
cancer cells

[255]

. It is also noteworthy to mention that, in addition to its role in

migration, invasion, and metastasis, MMP-9 is known to play a crucial role in
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angiogenesis as well as tumor formation

[256,257]

. Most relevantly, it has been shown

that the expression of MMP-9 is induced by STAT3 [267,268] . Indeed, overexpression
of constitutively active form of STAT3c in breast cells led to a significant upregulation
(up to 4-fold increase) of MMP-9 mRNA transcript. Added to that, these authors also
showed that MMP-9 expression correlates with that of activated STAT3 in human
breast cancer specimens. This is in accordance with another report that showed that
the inhibition of STAT3 abolishes the activity of MMP-9 in MDA-MB-231 cells [130].
Finally, Knockdown of STAT3 in the multidrug-resistant breast cancer, SK-BR3/EPR, cell line inhibited cell invasion and downregulated MMP-9 in these cells [258].
Interestingly, here the results showed that carnosol dramatically reduced the level of
STAT3, a transcription factor required for MMP-9 expression, and downregulated
MMP-9 in MDA-MB-231 cells. This led to a hypothesis stating that the depletion of
STAT3 by carnosol contribute, although maybe not solely, to the inhibition of
transcription of the MMP-9 gene, which results in the downregulation of MMP-9
protein expression and activity level.

Persistent activation of STAT3 has been described in several cancers, including breast
cancer. A crucial role of STAT3 in tumor onset and progression, tumor cell invasion,
metastasis, and angiogenesis has been largely demonstrated. Therefore, targeting
STAT3 is an attractive approach given that it assaults cancer on multiple fronts

[254]

.

Recently, carnosol was shown to attenuate activation of STAT3 signaling by inhibiting
its phosphorylation while having no effect on the inactive STAT3 in HCT116 human
colon cancer cells [248]. In agreement with this finding, the results of this current study
(section 1) also found that carnosol inactivated STAT3 signaling pathway in a panel
of breast cancer cell lines (MDA-MB-231, Hs578T, MCF-7, and T47D). Strikingly,

56
here we demonstrated that inactivation of STAT3 signaling in all breast cancer cell
lines tested involved a different mechanism. Indeed, targeting of total STAT3 protein
to proteasomal degradation was notable, hence suggesting that inhibition of STAT3
by carnosol involves a cancer-type specific mechanism(s). In recent years, several
potent and selective inhibitors of STAT3 of synthetic or natural origin have been
described. These inhibitors appear to act via a direct or indirect mode of action. While
indirect inhibitors block the upstream effectors regulating STAT3 activation, direct
inhibitors, on the other hand, block phosphorylation, dimerization, nuclear
translocation, and DNA binding of STAT3

[259,260]

. Several studies showed that

paeoniflorin (PF), a natural compound, suppressed growth, migration, invasion, and
tumor growth of U87, U251, T98G glioblastoma cells. Interestingly, PF was shown to
target STAT3 to proteasome degradation

[261,262]

. However, the exact mechanism

through which PF targets STAT3 to proteasome degradation remains unknown.
Similar to PF, this current study (section 1) found that carnosol also inhibits STAT3
signaling through a mechanism involving a ROS-dependent proteasome degradation
of STAT3 protein. Al Dhaheri et al. have previously shown that carnosol induced ROS
generation in a concentration-dependent manner in MDA-MB-231 cells. Here, in this
report, the results have shown that the inhibition of ROS accumulation by NAC also
restored the level of STAT3 protein. This strongly suggests that carnosol-mediated the
accumulation of ROS through targeting STAT3 to proteasome degradation. This
contributes, at least partly, to the inhibition of cell migration, invasion, metastasis, and
tumor growth of breast cancer. Further studies are needed to demonstrate the effect of
carnosol on STAT3 in tumors themselves. To the best of our knowledge, carnosol is
the first compound reported to specifically target STAT3 for proteasome degradation
in breast cancer.
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A large body of evidence supports the notion that ROS can also inhibit the metastasis
of breast cancer. Baicalin, for example, a natural flavonoid, was shown to suppress
migration/invasion of MDA-MB-231 cells via a ROS-mediated activation of p38/JNK
signaling pathway

[263]

. Besides, theaflavins, natural polyphenols, were shown to

inhibit migration and downregulate levels of MMP-2 and MMP-9 in MDA-MB-231
through a mechanism involving ROS generation

[264]

. Likewise, phenethyl

isothiocyanate (PEITC) and benzyl isothiocyanate (BITC), two phytochemicals, were
shown to inhibit migration and invasion of human non-small cell lung cancer cells
[265]

through a ROS-dependent mechanism

. Based on the findings of this study, we

hypothesize that ROS might contribute, albeit not solely, to the carnosol-mediated
inhibition of cellular migration, invasion, and tumor growth of TNBC through
proteasomal degradation of STAT3. Thus, this work, along with Al Dhaheri’s previous
findings [50] further suggests that carnosol may serve as a novel and effective anticancer
agent for the treatment of the highly invasive and metastatic TNBC. Finally, it is
noteworthy to mention that a large number of experiments carried out on animals
showed that carnosol is safe

[49,56–58]

. Here, this study showed that carnosol at

concentrations of 50 and 100 μM has no toxicity to chick embryos.
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3.2 Carnosol Activates UPR in a ROS-Dependent Manner in Breast Cancer
Cells
3.2.1 Results
3.2.1.1 Carnosol Induces ER-Stress Through Activating the Expression of
ATF4/CHOP and Promotes ATF6⍺ Cleavage
ROS generation has been recognized to induce ER-stress mediated cell death in variety
of cancer types

[266]

. The phytochemical carnosol has been reported to trigger ROS

production, induces activation of γH2AX, a marker of DNA damage, and causes
mitochondrial membrane potential depolarization in the TNBC cell line, MDA-MB
231

[50]

. This draws us to examine whether carnosol induces ER stress and activate

UPR system in breast cancer.

CHOP is an ER stress marker that is known to be activated upon growth arrest and
DNA damage

[267]

; therefore, MDA-MB-231 and Hs578T cells were treated with

different concentrations of carnosol, and CHOP level was evaluated. As shown in
Figure 9A (left side), CHOP protein expression increased as carnosol concentration
increases. However, when cells were pretreated with NAC (a ROS scavenger) for 1 h,
then treated with 50 μM and 100 μM of carnosol, the level of CHOP protein
dramatically decreased (Figure 9A, right side).

CHOP, in order to be expressed and activated upon ER stress, needs the transcription
factors ATF4 and cleaved form of ATF6⍺ to be recruited to its promoter [138,139]. For
this reason, we investigated the effect of carnosol treatment in ATF4 and cleaved
ATF6⍺ proteins levels in MDA-MB-231 and Hs578T cells. The results in Figures 9C
and 9D revealed that at high concentrations of carnosol, 50 μM and 100 μM, ATF4
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and cleaved ATF6⍺ (N) proteins levels were increased (left side); however, both
returned to a similar level as the control once treated with NAC (right side). This
demonstrate that carnosol stimulated ROS production, which acts as an upstream
inducer for ER stress, ultimately activates the two of the UPR sensors pathways, which
are ATF4/CHOP and ATF6⍺.
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Figure 9: Carnosol induces ER-stress through activating ATF4/CHOP expression and
stimulates ATF6⍺ cleavage.
(A, C and D) MDA-MB-231 and Hs578t cells were pretreated first with a ROS scavenger, NAC, and
vehicle (0.2% DMAS) for 1 hour, then, different concentrations of carnosol were added (50 µM and
100 µM), and cells were incubated for 24 hours. (B) T47D and MCF-7 cells were treated with different
concentrations of carnosol;50 µM and 100 µM for 24 hours. Whole cells lysate were resolved on 12.5%,
10% and 8% SDS-PAGE and examined by Western blotting for CHOP, ATF4 and cleaved ATF6⍺ ((P)
For total and (N) for cleaved ATF6⍺) proteins. Experiments were repeated 4 times.
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Figure 9: Carnosol induces ER-stress through activating ATF4/CHOP expression and
stimulates ATF6⍺ cleavage (Continued).
(A, C and D) MDA-MB-231 and Hs578t cells were pretreated first with a ROS scavenger, NAC, and
vehicle (0.2% DMAS) for 1 hour, then, different concentrations of carnosol were added (50 µM and
100 µM), and cells were incubated for 24 hours. (B) T47D and MCF-7 cells were treated with different
concentrations of carnosol;50 µM and 100 µM for 24 hours. Whole cells lysate were resolved on 12.5%,
10% and 8% SDS-PAGE and examined by Western blotting for CHOP, ATF4 and cleaved ATF6⍺ (P)
For total and (N) for cleaved ATF6⍺) proteins. Experiments were repeated 4 times.
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3.2.1.2 Carnosol Stimulates the Activation of IRE1⍺ and Splicing of XBP1
As the previous results showed that carnosol stimulated the activation of UPR
pathways, this drove us to investigate the effect of carnosol on the third sensor, which
is IRE1⍺ /XBP1. The phosphorylated form of IRE1⍺ is required for splicing the
mRNA of the transcription factor, XBP1, to further control the genes expression
involved in protein folding and trafficking [143,144].
Therefore, an examination of the total and phosphorylated form of IRE1⍺ in the
presence of carnosol treatment in TNBC was carried out. The result in Figure 10A (left
side) showed that the total and phosphorylated form of IRE1⍺ was increased the most
at 100 μM of carnosol treatment. Since phospho-IRE1⍺ protein expression increased,
this made us predict that XBP1s (the spliced mRNA) will increase as well. As
expected, carnosol treatment has stimulated the splicing of XBP1, which ultimately
increased the expression of spliced XBP1s (Figure 10B, left side). Moreover, to
investigate whether ROS accumulation, induced by carnosol, is needed to activate the
UPR sensor IRE1⍺ / XBP1 pathway, TNBC cells were pretreated with NAC for 1 hr;
then, carnosol was applied with different concentrations for 24 hr. Western Blot results
(Figure 10A and B, right side) revealed that upon the NAC application, phosphoIRE1⍺ and XBP1 protein expression levels decreased sharply to be similar to the nontreated cells. By this, carnosol has exhibited its ability to activate UPR sensors
pathways, including IRE1⍺/ XBP1through stimulation of ROS production.
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Figure 10: Carnosol stimulates the phosphorylation of IRE1⍺ and promotes the
splicing of XBP1.
(A and B) MDA-MB-231 and Hs578t cells were pretreated first with a ROS scavenger, NAC, and
vehicle (0.2% DMAS) for 1 hour, then, different concentrations of carnosol were added (50 µM and
100 µM), and cells were incubated for 24 hours. Whole cells lysates were resolved on 10% and 8%
SDS-PAGE and examined by Western blotting for phosphorylated IRE1⍺, total IRE1⍺ and XBP1s
proteins. Experiments were repeated 4 times.
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3.2.1.3 Carnosol Upregulates β-catenin and ER-Stress Chaperones
Beside ROS, β-catenin can also triggers early ER stress signaling via activating eIF2α
and increasing the expression of CHOP and p21, leading to immediate growth
inhibition and apoptosis in different cancers

[268]

. Our lab has previously shown that

carnosol significantly and dramatically increases p21 protein level in TNBC cells,
MDA-MB-231, causing cell cycle arrest [50]. Here in this study, we showed that CHOP
level increased in MDA-MB-231 and Hs578T upon carnosol treatment Figure 9A (left
side). This led to further evaluate the level of β-catenin in TNBC cells treated with the
carnosol. We found that Carnosol treatment caused a dramatic rise in the expression
of β-catenin in MDA-MB-231 cells (Figure 11A, left side); however, when cells
pretreated with NAC prior to addition of carnosol, β-catenin protein level sharply
declined (Figure 11A, right side). This result strongly suggest that ROS generation is
an early event that induce β-catenin expression, consequently, triggers early ER stress.

ER lumen chaperons and specialized enzymes are important to ensure protein folding
and trafficking. When misfolded proteins get accumulated upon stress, ER chaperon
proteins such as BiP will be released form the UPR sensors, holding the misfolded
proteins and letting the UPR to be activated. Hence, the level of BiP protein was
examined in cells treated with increasing concentration of carnosol. The result in
Figure 11B (left side) showed that the molecular chaperone Bip was increased by
carnosol in a dose-dependent manner. On the other hand, when ROS accumulation was
blocked by NAC, BiP expression in carnosol-treated cells was comparable to nontreated cells as shown in Figure 11B (right side side).
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Calnexin, Ero1-Lα and Protein disulfide isomerase (PDI) are ER specialized enzymes
that function in glycoprotein quality control, redox generation, and protein disulfide
isomerase, respectively. Therefore, we decided to study the effect of carnosol on these
specialized enzymes. Carnosol induced the unfolding protein response by
downregulating the protein expressions of PDI and Ero1-Lα (Figure 11C & 11D, left
side). However, no significant change was observed in the level of the calnexin as in
Figure 11E. Overall, this data indicates the impact of carnosol and its involvement in
regulating ER chaperons’ expression.

Figure 11: Carnosol upregulates β-catenin and ER-stress chaperones.
(A, B, C, and E) MDA-MB-231 cells were pretreated first with a ROS scavenger, NAC, and vehicle
(0.2% DMAS) for 1 hour, then, different concentrations of carnosol were added (50 µM and 100 µM),
and cells were incubated for 24 hours. Whole cells lysates were resolved on 10% and 8% SDS-PAGE
and examined by Western blotting for β-catenin, BiP, PDI, Ero1-Lα and calnexin proteins. Experiments
were repeated 4 times.
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Figure 11: Carnosol upregulates β-catenin and ER-stress chaperones(Continued).
(A, B, C, and E) MDA-MB-231 cells were pretreated first with a ROS scavenger, NAC, and vehicle
(0.2% DMAS) for 1 hour, then, different concentrations of carnosol were added (50 µM and 100 µM),
and cells were incubated for 24 hours. Whole cells lysates were resolved on 10% and 8% SDS-PAGE
and examined by Western blotting for β-catenin, BiP, PDI, Ero1-Lα and calnexin proteins. Experiments
were repeated 4 times.
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3.2.1.4 Carnosol-Induced Oxidative Stress Inhibits the Cell Survival Signaling
Akt/mTOR and Activates Protein Degradation Through Ubiquitination
Carnosol has shown to inhibit cell survival, induce apoptosis and autophagy in MDAMB-231 cells

[50]

. Therefore, we sought to examine the expression of Akt /mTOR

signaling, a major pathway in the growth and survival of cancer cells and inhibitor of
autophagy. Carnosol observes to downregulates Phospho-Akt and total-Akt expression
in MDA-MB-231 cell line at 24 h by immunoblotting (Figure 12A, left side).
Pretreatment of the cells with NAC for 1 h, and then cotreating them with carnosol for
24 h resulted in a significant increase in phospho-Akt and total-Akt in MDA-MB-231
cells as shown in Figure 12A, right side). Analysis of phospho-mTOR and total-mTOR
level in carnosol treated cells by Western Blotting was consistent with Akt results
(Figure 12B). There was a highly significant reduction in phospho-mTOR and totalmTOR in breast cancer cells when treated with carnosol (Figure 12B, left side), but
blocking ROS with NAC during carnosol treatment restores phospho-mTOR
expression (Figure 12B, right side). These outcomes suggest the anticancer effect of
carnosol on the cell survival signaling pathways.

Zhoa et al, showed that a decrease in mTOR activity increases overall protein
ubiquitination and degradation by the ubiquitin proteasome system [269] . This provoked
the author to examine whether inactivation of mTOR activity by carnosol enhances
overall protein ubiquitination. MDA-MB-231 cells were treated with 50 and 100 μM
carnosol and overall protein ubiquitination level was determined by Western Blotting
using ubiquitin antibody. The result revealed that treatment with carnosol caused a
marked increase in the total content of ubiquitinated proteins (Figure 12C). However,
when MDA-MB-231 cells were pretreated first with NAC for 1 h then carnosol was
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added, the overall protein ubiquitination level dramatically decreased. This result
implies a prosurvival pathway by dragging proteins to be degraded by proteasome
through ubiquitination.

Figure 12: Carnosol-induced oxidative stress constrains the cell survival signaling
Akt/mTOR and activates protein degradation through ubiquitination.
(A, B, and C) MDA-MB-231 cells were pretreated first with a ROS scavenger, NAC, and vehicle (0.2%
DMAS) for 1 hour, then, different concentrations of carnosol were added (50 µM and 100 µM), and
cells were incubated for 24 hours. Whole cells lysates were resolved on 12.5%, 10% and 8% SDSPAGE and examined by Western blotting for phosphorylated AKT, total AKT, phosphorylated mTOR,
total mTOR and ubiquitinated proteins. Experiments were repeated 3 times.
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Figure 12: Carnosol-induced oxidative stress constrains the cell survival signaling
Akt/mTOR and activates protein degradation through ubiquitination (Continued).
(A, B, and C) MDA-MB-231 cells were pretreated first with a ROS scavenger, NAC, and vehicle (0.2%
DMAS) for 1 hour, then, different concentrations of carnosol were added (50 µM and 100 µM), and
cells were incubated for 24 hours. Whole cells lysates were resolved on 12.5%, 10% and 8% SDSPAGE and examined by Western blotting for phosphorylated AKT, total AKT, phosphorylated mTOR,
total mTOR and ubiquitinated proteins. Experiments were repeated 3 timeS.

3.2.1.5 Carnosol Regulate Cell Death via Upregulating the Expression of P38
One of the most significant target of cancer treatment is inducing cell death, and
several studies have demonstrated the involvement of the MAPK P38 in regulating the
balance or switch between autophagy and apoptosis in cancer upon the induction of
ER stress

[166],[270,271]

. Our lab previously showed that carnosol induced autophagy

followed by activation of apoptosis in MDA-MB-231 cells. We sought to examine the
p38 MAPK pathway in carnosol-treated cells. Figure 13A (left side) shows a dosedependent increase in phosphor-p38 in carnosol-treated MDA-MB-231 cells.
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However, the ROS scavenger, NAC completely abolished p38 activation (Figure 13A,
right side). Other breast cancer cell lines, T47D and MCF7 (Figure 13B), showed an
increase in the pP38 level as the MDA-MB-231 cells. This result suggests a possible
involvement of P38 activation in carnosol-mediated ER stress, autophagy and/or
apoptosis. To further understand the mechanism of p38 involvement in cell death
decision, breast cancer cells were pretreated with p38 inhibitors (SB 203580 and SB
202190), for 1 h and carnosol was applied and then cleaved PARP (marker of
apoptosis) and LC3 II (marker of autophagy) protein level was assessed. As shown in
Figure 13C LC3 II level decreased in cell treated with p38 inhibitors in comparison to
control, suggests that p38 activation plays an important role in carnosol-induced
autophagy. Conversely, inhibition of p38 had no effect on the activation of apoptosis.
Apoptosis, demonstrated by cleaved PARP, occurred in cell treated with p38 inhibitors
at level comparable to control cells (Figure 13D). Altogether, our results suggest that
p38 activation is involved in the process of activation of autophagy and not apoptosis.
A putative downstream target of p38 is CHOP, which mediates ER stress-induced
autophagy, apoptosis, or inflammation

[272]

. Since CHOP was found previously to be

stimulated with carnosol treatment, this prompted us to evaluate CHOP level in cells
pretreated with SB 203580 and SB 202190 and then cotreated with carnosol for 24 hr.
Inhibiting p38 activation has sharply reduced the protein level of CHOP (Figure 13E).
Hence, we hypothesized that p38 might play a critical role in carnosol-induced CHOP
upregulation which in turn induces autophagy.
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Figure 13: Carnosol control cell death through upregulating P38 expression.
(A) MDA-MB-231 cells were pretreated first with a ROS scavenger, NAC, and vehicle (0.2% DMAS)
for 1 hour, then, different concentrations of carnosol were added (50 µM and 100 µM), and cells were
incubated for 24 hours. (B) MCF7 and T47D cell were treated with 50 µM and 100 µM of carnosol and
incubated for 24 hours. (C, D and E) MDA-MB-231 cells were pretreated first with P38 inhibitors, SB
203580 and SB 202190, and vehicle (0.2% DMAS) for 1 hour, then, different concentrations of carnosol
were added (50 µM and 100 µM), and cells were incubated for 24 hours. Whole cells lysates were
resolved on 12.5% and 10% SDS-PAGE and examined by Western blotting for phosphorylated P38,
total P38, LC4I/II, cleaved PARP and CHOP proteins. Experiments were repeated 3 times.

72

Figure 13: Carnosol control cell death through upregulating P38 expression
(Continued).
(A) MDA-MB-231 cells were pretreated first with a ROS scavenger, NAC, and vehicle (0.2% DMAS)
for 1 hour, then, different concentrations of carnosol were added (50 µM and 100 µM), and cells were
incubated for 24 hours. (B) MCF7 and T47D cell were treated with 50 µM and 100 µM of carnosol and
incubated for 24 hours. (C, D and E) MDA-MB-231 cells were pretreated first with P38 inhibitors, SB
203580 and SB 202190, and vehicle (0.2% DMAS) for 1 hour, then, different concentrations of carnosol
were added (50 µM and 100 µM), and cells were incubated for 24 hours. Whole cells lysates were
resolved on 12.5% and 10% SDS-PAGE and examined by Western blotting for phosphorylated P38,
total P38, LC4I/II, cleaved PARP and CHOP proteins. Experiments were repeated 3 times.
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3.2.2 Discussion
Studies have showed that some cancers are more sensitive to ROS than normal cells
[149]

, thus, targeting ROS induction could be an effective approach for killing cancer

cells selectively without causing significant toxicity to normal cells

[154,155]

.

Additionally, several reports have discussed the beneficial effects of ROS production
on chemotherapy-induced cell death in cancer cells [147–149]. Therefore, finding a new
drug that stimulates ROS production and ultimately leads to UPR activation is
considered a goal for new effective therapeutic approaches in cancer treatment.

Currently used anticancer therapeutics have represented limitations due to unfavorable
side effects and drug resistance [273]. Thus, scientists need to find new agents to develop
and expand more reliable treatments. Plant-derived drugs are showing curative
anticancer potential, hence, clarifying how these natural compounds interact with
cellular targets is important. Affecting the increase of ER stress and UPR related
proteins may perhaps represent an interesting approach to modify the homeostasis of
the ER in cancer cells to activate autophagy and apoptosis. Numerous natural
compounds have been shown to induce ER stress-related cells death in malignant cells
[274]

. For example, saxifragifolin D (found in Androsace umbellate) was reported to

induces ROS which in turn leads to growth inhibition via apoptosis [275]. Another study
has showed that a curcuminoid derivative called MTH-3 induced apoptosis
intrinsically and extrinsically by ER stress signals in MDA-MB-231 human breast
cancer cell line [276]. Patacsil et al. revealed that γ-tocotrienol (a vitamin E compound)
has stimulated ER stress-mediated apoptosis as verified by gene expression microarray
analysis in breast cancer cell lines, MDA-MB-231 and MCF-7. Indeed, microarray
results highlighted the modulation of genes expression involved in the ER stress
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response, such as ATF3 (a target gene for ATF4); the authors showed that ATF3 had
a critical role in γ-tocotrienol-induced apoptosis in MCF-7 cell line. Additionally, γtocotrienol has upregulted the ER stress-related protein markers BiP, PERK , ATF4
and IRE1α in both MDA-MB-231 and MCF-7 cells [277]. A study by Aghaei et al. has
demonstrated the antibreast cancer activity of pimpinelol (a lactone found in
Pimpinella haussknechtii), where it induces apoptosis via upregulating the protein
expression involve in ER stress and increase protein aggregation. Results were shown
using fluorescence microscopy analysis and mRNA expression of ATF4, CHOP,
GADD34, and TRIB3

[278]

. These studies proposed a promising potential of how

natural compounds can act as important chemical molecules that are able to modulates
and induces ER stress to further cause cancer cell death.
In this part of the study (2nd section), the polyphenolic compound, carnosol, was shown
to induce ROS-dependent ER stress through upregulating the three main UPR sensor
pathways and their downstream targets which are ATF4/CHOP, ATF6⍺ and
IRE1⍺/XBP1. Moreover, β-catenin found to be stimulated by carnosol, and considered
to be an upstream trigger of ER stress. In addition, a reduction in the cell survival
signaling Akt/mTOR was observed with carnosol treatment which consequently
activates protein degradation through ubiquitination.

The UPR is a cellular stress response that start in the ER, and controlled by three
different sensors, IRE1α, PERK, and ATF6⍺. Usually the ER resident chaperones,
such as BiP is bound to the ER luminal domain of the three sensors, retaining them in
an inactive state

[279]

. Under stress conditions that lead to accumulatedunfolded or

misfolded proteins causing an ER stress, BiP detach from IRE1⍺ and PERK, letting
the sensors to form homodimers or oligomers, and then through autophosphorylation,

75
it activates their downstream signals. Also, the release of BiP cause the cleavage and
activation of ATF6⍺ to transfer to the nucleus and activates the transcription of
different ER chaperones [280].

In response to UPR activation, PERK gets activated, consequently attenuates the
translation of mRNA and preventing the delivery of new proteins into the ER
compartment. This action is mediated by the activation of eIF2α which block proteins
translation

, but not absolute blockade. Indeed, in the meantime, active eIF2α

[281]

paradoxically positively regulates the translation of the transcription factor ATF4 [139].
In turn, ATF4 regulates the expression of genes implicated in the survival and
restoration of normal cellular homeostasis such as CHOP

[282]

. The CHOP gene, in

contrast to ATF4, it upregulates the expression of genes involve in growth arrest, DNA
damage inducible genes and apoptotic pathway

[283,284]

. ATF4 considered as a key

signal for autophagy-induced by ER stress, and subsequent upregulation of CHOP
switches autophagy into apoptosis. This switch is happening between ATF4 and
CHOP in the PERK cascade [285,286]. Upregulation of ATF4 and CHOP were found to
induces autophagy in different cancer types

[287,288]

. Another study showed that the

knockout of CHOP protein in mice model have revealed a lower apoptotic rate for ER
stress response

[289]

. Here, carnosol has been found to induce the upregulation of

ATF4/CHOP in breast cancer cells in response to ROS induction. This action was
further evaluated by treating the cells with NAC, a ROS scavenger, were the
expression of ATF4/CHOP was completely abolished.
IRE1α is another pathway which gets activated upon ER stress, BiP dissociate from
IRE1α receptor letting dimerization and autophosphorylation to happen, and
consequently converting IRE1α into its active state. Active IRE1α triggers its
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endonuclease activity to splice the mRNA of XBP1, which encodes for a transcription
factor targeting genes involved in prosurvival responses

[290]

, enhances protein

folding, transport and functions, and resolves misfolded proteins [291,292]. On the other
hand, active IRE1α triggers another downstream signal through post-transcriptional
modification of different substrates that tends to trigger apoptosis [293]. When ER stress
occurs, IRE1α gets activated rapidly, and when ER stress is transformed to chronic
stress, the signal of IRE1α is weakened

[294,295]

through dephosphorylation,

ubiquitination and degradation [296]. Breast cancer cells have been treated with carnosol
and the activation of IRE1α has been evaluated by Western Blotting. IRE1α
phosphorylation showed an increase in a concentration dependent manner with
carnosol treatment, meanwhile, an addition of NAC eliminates the activation,
suggesting the importance of ROS in the induction of UPR.
ATF6 has two homologous which are ATF6α and ATF6β. Following UPR activation,
ATF6α moves to the Golgi apparatus where it is cleaved by the proteases site-1 (S1P)
and site-2 (S2P) and activated. Active (cleaved) ATF6α translocates to the nucleus and
upregulates the transcription of XBP1 mRNA and then collaborates with IRE1α to
produce a spliced, mature XBP1s mRNA

[297]

. XBP1 binds to ATF6 forming a

complex that is involved in the expression of ER chaperones [298] to further stimulate
protein folding, secretion and ER-related protein degradation in parallel pathways
[299,300(p. 1)]

. While ATF6 activity is mainly to act as prosurvival signal, during severe

and prolonged ER stress, it can enhance CHOP expression that is associated with cell
death

[301]

. In agreement with these reports, we also found that carnosol induced an

upregulation of CHOP.
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The proper protein folding, and assembly is supported and monitored by a number of
ER

resident

proteins

including

chaperones,

glycosylating

enzymes,

and

oxidoreductases. One of the fundamental ER chaperones is BiP (Grp78) which
responsible for the activation of the three main sensors and bind to misfolded proteins
to engage an optimal UPR response [302]. BiP has been required for cancer cell survival,
proliferation and angiogenesis

[303]

, besides, several studies have reported an

upregulation of BiP in solid tumors in various organs [304–306]. PDI is another chaperon
that function as a thioldisulfide oxidoreductase and catalyze disulfide bonds in newly
synthesized proteins

[307]

. Findings on the role of PDI in cancer have illustrated a

prooncogenic and prosurvival function in addition to resistance to cancer therapy [303].
Lovata and collaborators revealed that treating melanoma cells with bacitracin, a PDI
inhibitor, enhanced the stress response and the induction of apoptosis in the presence
of chemotherapeutic drugs [308]. An additional ER resident protein is Ero1-Lα, a protein
disulfide oxidase that has a role in the formation of disulfide bonds of cell-surface and
secreted proteins. It has been reported that Ero1-Lα is highly upregulated in different
types of cancers and found to be associated with breast cancer poor prognosis

[309]

.

Targeting the previously discussed ER chaperons and resident proteins is a promising
approach to treat cancer. Thus, the expression of BiP, PDI, Ero1-Lα and calnexin have
been assessed upon carnosol treatment, BiP was increased while PDI, Ero1-Lα were
decreased, while calnexin was constantly expressed, suggesting their involvement in
UPR and inducing cell death in breast cancer.
β-Catenin is an essential component of the WNT signaling pathway [310], and has been
implicated in cell proliferation and migration of multiple myloma and was investigated
as a promising therapeutic target [311,312]. A study by Raab et al. revealed that β-catenin
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induces apoptosis through activating UPR. An inhibition of protein kinase C (PKC)
leads to accumulation of β-catenin by inhibiting phosphorylation which is necessary
for its proteasomal degradation. Consequently, accumulated β-catenin leads to growth
arrest via the induction of UPR which ultimately leads to apoptosis [268]. Interestingly,
we found that carnosol dramatically upregulated β-catenin through a ROS-dependent
mechanism. Hence, it is legitimate to speculate that β-catenin might be involved in
carnosol-induced ER stress, autophagy and/or cell death.

The Akt/mammalian target of rapamycin (mTOR) cascade is one of the most
frequently activated signaling pathways in human cancer [313].The activation of Akt is
through phosphorylation, phospho-Akt inhibits TSC1/2 leading to activate mTOR.
mTOR is kwon to regulate overall protein turnover and thus promoting cellular growth
and proliferation. Moreover, the Akt/mTOR cascade is frequently hyperactivated in
many cancers, including breast cancer

[314] ,

, and is important for aggressive tumor

growth and cell survival. A study by Woo and collaborators, investigated the inhibition
of Akt/mTOR pathway in breast cancer cells using a combination therapy (MK-2206,
Akt inhibitor and rapamycin, mTOR inhibitor). The results have dementated the
induction of apoptosis in vitro and inhibited tumor growth in vivo, suggesting that
Akt/mTOR has emerged as potential target for breast cancer therapy [315]. During the
activation of UPR, autophagy has been shown to be an adaptive response, in order to
help cells to restore ER homeostasis, or promoting to ER stress-induced cell death
[289,316]

. A study by Zhaou and coauthors have indicated that ampelopsin (a flavonol

mainly found in Ampelopsis grossedentata) induced ER stress, which consequently
leading to protective autophagy by downregulating Akt/mTOR pathway. This suggest
that targeting the cascade of ER stress activation through targeting Akt/mTOR may be
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a useful strategy in treating breast cancer

[317]

. Interestingly, we found that carnosol

downregulated the level of total mTOR and total AKT probably through targeting
these two proteins to proteasome degradation. Indeed, we showed that carnosol
induces an increase in the overall level of ubiquitinated of proteins suggesting an
activation of the ubiquitin proteasome system.

One of the most important targets of cancer therapy is inducing cell death, and p38 is
known to be involved in regulating the balance or switch between autophagy and
apoptosis in cancer upon the induction of ER stress [166],[270,271]. Liu et al. studied the
anticancer effects of Shikonin, a botanical drug extracted from Lithospermum
erythrorhizon, in human melanoma A375 cells. They found that Shikonin induced p38
activation via ROS-mediated ER stress, leading to protective autophagy at the
beginning; later, accumulated damage in the cells induced apoptosis [318]. In addition,
Jiang et al. revealed that selenite induced a switch to apoptosis from autophagy via
p38 pathway in human leukemia NB4 cells. This happens when selenite induces the
disassociated of p38 from the PERK complex, and p38 becomes phosphorylated,
which consequently leads to the activation of eIF2α. Hence, this event enhanced the
binding of ATF4 to the CHOP promoter, which ultimately led to apoptosis. On the
other hand, p38 hindered the activation of eIF4E, which inhibited the association of
ATF4 with the MAP1LC3B promoter, resulting in autophagy suppression

[319]

. This

study showed how p38 has a differential modulation mode of activation for eIF2α and
eIF4E, affecting ATF4 binding to the promoters of target genes. Therefore, p38 has
influenced the transcription of essential proteins and the switch from autophagy to
apoptosis.
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To date, several pieces of evidence have shown that some of the polyphenols [274,318,320]
or natural compounds

[319]

exhibit their anticancer activity through ROS-induced ER

stress and involvement of p38 activation in regulating cell death. Additional,
preclinical studies reveal that bioactive dietary polyphenols exert anticancer effects by
inducing ROS-mediated cytotoxicity in cancer cells [321]. This attracted the interest to
further investigate the polyphenolic compound carnosol, as it has been proved that it
induces ROS-mediated autophagy and apoptosis in TNBC

[50]

. Nevertheless, the role

of carnosol in ROS-activate p38 is still vague and finding the correlation will guide
the search for new targeted drugs for the aggressive TNBC. These studies directed the
research toward investigation of the P38 activity in carnosol induce cell death. The
data in this current study showed that carnosol has downregulated phospo-P38 via a
ROS-dependent mechanism. Then, the effect of inhibiting P38 activity was carried out
by using P38 inhibitors (SB 203580 and SB 202190), and the result reveled that p38
activation plays an important role in carnosol-induced autophagy. On the other hand,
loss of p38 resulted in apoptosis enhancement by increasing cleaved PARP protein.
This proposed that breast cancer cells treated with carnosol, involve P38 more in
inducing autophagy than apoptosis. Strikingly, inhibition of p38 activation by the two
inhibitors blocked carnosol-induced ER stress as no CHOP activation was seen in SB
203580 and SB 202190-treated MDA-MB-231 cells.

Overall, carnosol was shown to inhibit breast cancer cells through induction of ERstress followed by autophagy and subsequent activation of apoptosis.
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3.3 Carnosol is a Novel Inhibitor of p300 Acetyltransferase in Breast Cancer
3.3.1 Results
3.3.1.1 Carnosol Induced Histone Hypoacetylation in Breast Cancer Cells
HATs are becoming an important target for cancer treatments as it is involved in cancer
progression pathways [322], hence this derives the authors for further studying the anticancer effect of carnosol in triple-negative breast cancer cell lines. The overall
acetylation status of histone H3 and histone H4 in carnosol-treated breast cancer cells
was examined. The results revealed that carnosol induced an overall decreased in the
acetylation level of histone H3 and H4 in MDA-MB-231 (Figure 14A) triple-negative
breast cancer cells. Thereafter, an assessment of the acetylation status of specific lysine
residues known to be substrates for acetylation was carried out using antibodies against
acetylated H3K56, H3K14, H3K9, H4K16, and H4K5. Carnosol showed a differential
effect on the acetylation of different residues (Figure 14B). While carnosol had little
impact on the acetylation of H4K5 and H4K16, it dramatically reduced the level of
acetylation of H3K56, H3K9, and H3K14 in MDA-MB-231 cells (Figure 14B). To
rule out that the carnosol-induced histone hypoacetylation is a result of upregulated
HDAC activity, MDA-MB-231 cells were first pre-treated with the HDAC inhibitor,
Trichostatin A (TSA), and then treated with carnosol for 24 h. As shown in Figure
14C, inhibition of HDAC activities by TSA had no effect on carnosol-induced histone
hypoacetylation of histone H3K56. Therefore, these results suggest that carnosol
might induce histone hypoacetylation by affecting the activity of histone
acetyltransferase(s) in breast cancer cells. Additionally, considering that carnosol
induced histone hypoacetylation at specific residues suggests that it exerts its effect on
particular HATs.
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Figure 14: Carnosol stimulates histone hypoacetylation in vivo in breast cancer cells.
(A) Carnosol promotes overall histone H3 and H4 hypoacetylation. MDA-MB 231 cells were treated
with vehicle (0.2% DMSO) or with carnosol (50 µM and 100 µM), then cells were collected, and
proteins were extracted and subjected to Western Bloting analysis for the acetylated histone H3 and
histone H4. (B) Carnosol induces histone hypoacetylation at specific residues. All cells were collocated,
and proteins were extracted and subjected to Western Blotting analysis for the acetylated H3K56,
H3K14, H3K9, H4K16 and H4K5. (C) HAT, and not HDAC, are implicated in carnosol-induced histone
hypoacetylation. Trichostatin A (TSA) has no influence on carnosol-induced histone H3K(56)
hypoacetylation, one of p300 substrates. Cells were pre-treated with or without TSA (400 nM) for 4
hours and then treated with carnosol (50 and 100 µM) for 24 hours. Whole cell lysate was resolved on
15% SDS gel and probed with acetyl-H3K56 antibody. Data shown are representative of three
independent experiments. carried at different times using different protein preparations. Bands
intensities were quantified using the ImageJ software (National Institute of Health, USA).
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Figure 14: Carnosol stimulates histone hypoacetylation in vivo in breast cancer cells
(Continued).
(A) Carnosol promotes overall histone H3 and H4 hypoacetylation. MDA-MB 231 cells were treated
with vehicle (0.2% DMSO) or with carnosol (50 µM and 100 µM), then cells were collected, and
proteins were extracted and subjected to Western Bloting analysis for the acetylated histone H3 and
histone H4. (B) Carnosol induces histone hypoacetylation at specific residues. All cells were collocated,
and proteins were extracted and subjected to Western Blotting analysis for the acetylated H3K56,
H3K14, H3K9, H4K16 and H4K5. (C) HAT, and not HDAC, are implicated in carnosol-induced histone
hypoacetylation. Trichostatin A (TSA) has no influence on carnosol-induced histone H3K(56)
hypoacetylation, one of p300 substrates. Cells were pre-treated with or without TSA (400 nM) for 4
hours and then treated with carnosol (50 and 100 µM) for 24 hours. Whole cell lysate was resolved on
15% SDS gel and probed with acetyl-H3K56 antibody. Data shown are representative of three
independent experiments. carried at different times using different protein preparations. Bands
intensities were quantified using the ImageJ software (National Institute of Health, USA).

3.3.1.2 Carnosol Downregulates p300 and PCAF in MDA-MB-231
Next, the protein expression level of p300, PCAF, GCN5, and hMOF histone
acetyltransferases were examined by Western Blot. Carnosol was found to induce a
dramatic decrease in the protein level of p300 and PCAF in MDA-MB-231 (Figure
15A) and Hs578T (Figure 15E) cells in a concentration-dependent manner. On the
other hand, the protein level of GCN5 and hMOF remained constant in carnosoltreated cells. As expected, carnosol did not affect the expression level of HDAc1 and
HDAC, as shown in Figure 15A. The previous results indicate that carnosol
specifically downregulates p300 and PCAF in breast cancer cells.

To understand the mechanism by which carnosol downregulated p300 and PCAF, first,
an examination of p300 and PCAF mRNA transcript level in MDA-MB-231 cells
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treated with and without carnosol was carried out. RT-PCR showed no significant
alterations in mRNA levels for both transcripts between control and carnosol-treated
cells (Figure 15BAfterward, the author sought to assess whether carnosol influences
p300 and PCAF constancy. To answer this question, cells were first pre-treated with
cycloheximide, an inhibitor of eukaryotic translation, and after that treated with
carnosol. As shown in Figure 15D, carnosol caused a decrease in the expression level
of p300 and PCAF in the presence of cycloheximide. Altogether, these results strongly
suggest that carnosol downregulated p300 and PCAF protein levels at the posttranslational level, probably via targeting them for degradation. Additionally, the
author hypothesized that histone hypoacetylation in response to carnosol is a
consequence, at least partly, of p300 and PCAF downregulation.
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Figure 15: Carnosol downregulates the expression of p300 and PCAF in breast cancer
cells.
(A) P300 and PCAF protein levels were decreased in carnosol-treated MDA-MB-231 cells. MDA-MB231 cells were treated with vehicle (0.2% DMSO) or indicated concentrations of carnosol (50 µM and
100 µM) and whole cell lysates were resolved in 6% SDS-PAGE and subjected to Western Blot analysis
for the indicated proteins. The Data shown are illustrative of three independent experiments. (B, and C)
Carnosol does not affect the mRNA transcript levels of p300 and PCAF. Total RNA from cells treated
with carnosol or vehicle were used to amplify the PCAF and p300 transcripts by RT- and qRT-PCR.
RT- and qRT-PCR were repeated two times. (D) Carnosol downregulates p300 and PCAF proteins in
cycloheximide-pre-treated cells. Cells were pre-treated with cycloheximide (an inhibitor of de novo
protein synthesis) for 2 hours and, then treated with or without carnosol (50 µM and 100 µM). Whole
cell lysates were collected and exposed to Western Blot for p300 and PCAF. (E) Downregulation of
p300 and PCAF proteins expression in Hs578T cells treated with carnosol. Hs578T cells were treated
with vehicle (0.2% DMSO) or indicated concentrations of carnosol (50 µM and 100 µM) and whole
cell lysates were resolved in 6% SDS-PAGE and subjected to Western Blot analysis for P300 and PCAF
proteins. Bands intensities were quantified using the ImageJ software (National Institute of Health,
USA).
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Figure 15: Carnosol downregulates the expression of p300 and PCAF in breast cancer
cells (Continued).
(A) P300 and PCAF protein levels were decreased in carnosol-treated MDA-MB-231 cells. MDA-MB231 cells were treated with vehicle (0.2% DMSO) or indicated concentrations of carnosol (50 µM and
100 µM) and whole cell lysates were resolved in 6% SDS-PAGE and subjected to Western Blot analysis
for the indicated proteins. The Data shown are illustrative of three independent experiments. (B, and C)
Carnosol does not affect the mRNA transcript levels of p300 and PCAF. Total RNA from cells treated
with carnosol or vehicle were used to amplify the PCAF and p300 transcripts by RT- and qRT-PCR.
RT- and qRT-PCR were repeated two times. (D) Carnosol downregulates p300 and PCAF proteins in
cycloheximide-pre-treated cells. Cells were pre-treated with cycloheximide (an inhibitor of de novo
protein synthesis) for 2 hours and, then treated with or without carnosol (50 µM and 100 µM). Whole
cell lysates were collected and exposed to Western Blot for p300 and PCAF. (E) Downregulation of
p300 and PCAF proteins expression in Hs578T cells treated with carnosol. Hs578T cells were treated
with vehicle (0.2% DMSO) or indicated concentrations of carnosol (50 µM and 100 µM) and whole
cell lysates were resolved in 6% SDS-PAGE and subjected to Western Blot analysis for P300 and PCAF
proteins. Bands intensities were quantified using the ImageJ software (National Institute of Health,
USA).

3.3.1.3 Carnosol Induces ROS-Dependent Proteasome Degradation of p300 and
PCAF
Al Dhaheri et al. have previously reported that carnosol triggered autophagy in MDAMB-231 breast cancer cells [50]. Therefore, the author decided to explore whether p300
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and PCAF were degraded through autophagy. It has been found that the blockade of
early-stage autophagy (autophagosome formation) by 3-MA and late-stage autophagy
(autophagolysosome formation) by CQ failed to rescue p300 and PCAF protein levels
(Figure 16A). Thus, this led the author to exclude the possibility of
autophagolysosomal degradation as a mechanism responsible for the decrease of the
two HATs.

Afterward, the author had tested the possible involvement of proteasomal activity in a
carnosol-mediated decrease of both p300 and PCAF. Firstly, MDA-MB-231 cells were
pre-treated with the proteasome inhibitor MG-132 or bortezomib for 1 h before
carnosol was added. As shown in Figure 16B, both proteasome inhibitors were able
efficiently to restore the levels of p300 and PCAF proteins to levels comparable to
untreated cells. This result clearly revealed that carnosol targets p300 and PCAF to
proteasome degradation. Recently, Alsamri et al. have reported that carnosol
stimulated proteasome degradation of STAT3 protein through a ROS-dependent
mechanism

[323]

. This encouraged the author to check whether ROS production

implicates the degradation of p300 and PCAF. Blockade of ROS accumulation using
NAC, a ROS scavenger, was able to efficiently prevent carnosol-mediated proteasome
degradation of the two HATs in both MDA-MB-231 (Figure 16C) and Hs578T (Figure
16F) cells. Altogether, these outcomes demonstrate that carnosol targets p300 and
PCAF to ROS-dependent proteasome degradation.

Having demonstrated that proteasome inhibition (Figure 16B) and blockade of ROS
accumulation (Figure 16C) efficiently restored the levels of p300 and PCAF to those
observed in the untreated control cells, the author next sought to examine whether this
was also associated with restoration of the histone acetylation status. Interestingly, it
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has been found that the inhibition of HAT degradation by proteasome inhibitors
(Figure 16D) or ROS scavenger (Figure 16E) failed to restore the histone acetylation
of H3K56, a preferred p300 substrate, in MDA-MB-231. Also, NAC had no effect on
carnosol-induced hypoacetylation of H3K56 in Hs578T cells (Figure 16G). Overall,
these data strongly suggested that, in addition to promoting p300 and PCAF
degradation, carnosol might also exert its anti-breast cancer effect via direct inhibition
of HAT activity.
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Figure 16: Carnosol stimulates a ROS-dependent proteasome degradation of p300 and
PCAF in breast cancer cells.
(A) The protein expression of p300 and PCAF proteins levels in MDA-MB-231 cells pre-treated with
autophagy inhibitors. Cells were pretreated with or without autophagy inhibitors (50 mM of 3-MA and
50 μM of CQ) for 1 hour and then 50 µM and 100 µM of carnosol was added and incubation for another
24 hours. (B) Carnosol causes proteasome-dependent degradation of p300 and PCAF. MDA-MB-231
were pre-treated for 1 hour with or without the proteasome inhibitors (15 μM of MG-132 or 25 nM of
Bortezomib), then indicated concentrations of carnosol were applied. (C) Proteasome degradation of
p300 and PCAF in a ROS-dependent manner. MDA-MB-231 cells were pre-treated for 1 hour with the
ROS scavenger, NAC, then carnosol (50 and 100 μM) was added. Whole cells lysates were resolved on
6% SDS-PAGE and evaluated by Western Blotting for p300 and PCAF proteins. (D, E) Restore of p300
and PCAF expression, by proteasome inhibitors (D) and ROS scavenger (E) did not rescue the
acetylation of H3K56, a preferred p300 substrate. (F) Carnosol stimulates a ROS-dependent degradation
of PCAF and P300 in Hs578T cells. Hs578T cells were pre-treated for 1 hour with the ROS scavenger,
NAC, then carnosol (50 and 100 μM) was added. Whole cells lysates were resolved on 6% SDS-PAGE
and evaluated by Western Blotting for p300 and PCAF proteins. (G) NAC did not restore the acetylation
of H3K56, a preferred p300 substrate. Whole cells lysates were resolved on 15% SDS-PAGE and
evaluated by Western Blotting for acetylated H3K56. Bands intensities were quantified using the
ImageJ software (National Institute of Health, USA).
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Figure 16: Carnosol stimulates a ROS-dependent proteasome degradation of p300 and
PCAF in breast cancer cells (Continued).
(A) The protein expression of p300 and PCAF proteins levels in MDA-MB-231 cells pre-treated with
autophagy inhibitors. Cells were pretreated with or without autophagy inhibitors (50 mM of 3-MA and
50 μM of CQ) for 1 hour and then 50 µM and 100 µM of carnosol was added and incubation for another
24 hours. (B) Carnosol causes proteasome-dependent degradation of p300 and PCAF. MDA-MB-231
were pre-treated for 1 hour with or without the proteasome inhibitors (15 μM of MG-132 or 25 nM of
Bortezomib), then indicated concentrations of carnosol were applied. (C) Proteasome degradation of
p300 and PCAF in a ROS-dependent manner. MDA-MB-231 cells were pre-treated for 1 hour with the
ROS scavenger, NAC, then carnosol (50 and 100 μM) was added. Whole cells lysates were resolved on
6% SDS-PAGE and evaluated by Western Blotting for p300 and PCAF proteins. (D, E) Restore of p300
and PCAF expression, by proteasome inhibitors (D) and ROS scavenger (E) did not rescue the
acetylation of H3K56, a preferred p300 substrate. (F) Carnosol stimulates a ROS-dependent degradation
of PCAF and P300 in Hs578T cells. Hs578T cells were pre-treated for 1 hour with the ROS scavenger,
NAC, then carnosol (50 and 100 μM) was added. Whole cells lysates were resolved on 6% SDS-PAGE
and evaluated by Western Blotting for p300 and PCAF proteins. (G) NAC did not restore the acetylation
of H3K56, a preferred p300 substrate. Whole cells lysates were resolved on 15% SDS-PAGE and
evaluated by Western Blotting for acetylated H3K56. Bands intensities were quantified using the
ImageJ software (National Institute of Health, USA).
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3.3.1.4 Carnosol Inhibits p300 Acetyltransferase Activity In Vitro
The ability of carnosol to prevent lysine acetyltransferase activity has been tested in a
cell-free system using HeLa nuclear extract (NE) as a source for HATs or recombinant
p300. The results revealed that carnosol significantly inhibited HAT activity in a
concentration-dependent manner in both NE- (Figure 17A) and recombinant p300based (Figure 17F) HAT assay, suggesting that carnosol is an inhibitor of
acetyltransferase activity. Afterward, the author sought to determine whether carnosol
is a specific or pan-HAT inhibitor. Toward this, in vitro acetylation assay was used
with purified histone H3 and recombinant p300, PCAF, and GCN5 acetyltransferases.
Carnosol was able efficiently to inhibit p300-dependent histone acetylation (Figure
17B) while it showed no significant detectable inhibition of PCAF (Figure 17C) and
GCN5-dependent histone acetylation (Figure 17D). A test for the ability of carnosol
to hinder p300 HAT activity using core histones as a substrate was done. As shown
in Figure 17E, carnosol also effectively inhibited the acetylation of H3K56 in this
assay. Altogether, these results recognized carnosol as a new natural specific inhibitor
of p300 activity.
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Figure 17: Carnosol is a specific inhibitor for p300 in vitro.
(A) Carnosol found to inhibit histone acetylation in vitro. HAT assay and using HeLa nuclear extract in
the presence of increasing concentrations of carnosol (25 μM, 50 μM and 100 μM). Values represented
of three independent experiments that were carried out in triplicate and presented as mean ± SEM. (**p
< 0.005, ***p < 0.001). (B-D) Carnosol inhibits P300 specifically (B) but don’ts inhibits PCAF (C) or
GCN5 (D). HAT assay was implemented using p300 catalytic domain (aa 1284-1673), recombinant
PCAF and GCN5, recombinant H3 with or without indicated concentration of carnosol. HAT activity
was evaluated by Western Blotting scoring for acetylated histone H3. (E) HAT assay was carry out
using recombinant p300 catalytic domain (aa 1284-1673), core histones and with or without indicated
concentrations of carnosol and HAT activity was measure as in (B). (F) In vitro HAT experiment using
recombinant p300 in the present of vehicle (0.2% DMSO) and different concentrations of carnosol (25
μM, 50 μM and 100 μM). Values presented in percent in which results are calculated from three
independent experiments performed in triplicate and presented as mean ± SEM. (**p < 0.005, ***p <
0.001). Bands intensities were quantified using the ImageJ software (National Institute of Health, USA).
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Figure 17: Carnosol is a specific inhibitor for p300 in vitro (Continued).
(A) Carnosol found to inhibit histone acetylation in vitro. HAT assay and using HeLa nuclear extract in
the presence of increasing concentrations of carnosol (25 μM, 50 μM and 100 μM). Values represented
of three independent experiments that were carried out in triplicate and presented as mean ± SEM. (**p
< 0.005, ***p < 0.001). (B-D) Carnosol inhibits P300 specifically (B) but don’ts inhibits PCAF (C) or
GCN5 (D). HAT assay was implemented using p300 catalytic domain (aa 1284-1673), recombinant
PCAF and GCN5, recombinant H3 with or without indicated concentration of carnosol. HAT activity
was evaluated by Western Blotting scoring for acetylated histone H3. (E) HAT assay was carry out
using recombinant p300 catalytic domain (aa 1284-1673), core histones and with or without indicated
concentrations of carnosol and HAT activity was measure as in (B). (F) In vitro HAT experiment using
recombinant p300 in the present of vehicle (0.2% DMSO) and different concentrations of carnosol (25
μM, 50 μM and 100 μM). Values presented in percent in which results are calculated from three
independent experiments performed in triplicate and presented as mean ± SEM. (**p < 0.005, ***p <
0.001). Bands intensities were quantified using the ImageJ software (National Institute of Health, USA).
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3.3.1.5 Carnosol Inhibits p300 Acetyltransferase Activity by Directly Competing
with Acetyl CoA In Vitro
A collaborative work showed that in silico molecular docking studies that carnosol
inhibits the acetyltransferase activity of p300 by hindering the entrance of the acetylCoA binding pocket of the catalytic domain [324].
To further confirm the in silico findings, in vitro HAT assay with carnosol,
recombinant histone H3, and increasing concentrations of acetyl-CoA were carried
out. As shown in Figure 16, increasing the concentration of acetyl-CoA up to 400 μM
led to restoring the acetylation of H3K56 by p300. These data, alongside the molecular
docking data, validates that carnosol inhibits p300 acetyltransferase activity by directly
competing with acetyl-CoA binding within the acetyl-CoA binding pocket of the
catalytic domain of p300.
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Figure 18: Carnosol competes with acetyl-CoA in the binding to the P300 catalytic
domain.
Recombinant p300 catalytic domain (aa 1284-1673) was incubated with recombinant histone H3 and
increasing concentrations of acetyl-CoA in the presence of 50 µM carnosol. Histone acetylation was
monitored by Western blotting scoring of acetylated H3K56. Data shown are representative of three
independent experiments. Bands intensities were quantified using the ImageJ software (National
Institute of Health, USA).

3.3.2 Discussion
Here, in the third section of the study, carnosol, a natural polyphenol and major
constituent of sage, rosemary, and oregano have been found to induce histone
hypoacetylation in breast cancer cells, MDA-MB-1231 and Hs578T. In addition,
carnosol constrained the activity of p300 acetyltransferase in vitro and stimulated its
ROS-dependent proteasome degradation along with PCAF acetyltransferase. Lastly,
carnosol is reported to hinders the activity of p300 acetyltransferase by obstructing the
binding of acetyl-CoA to its pocket in the catalytic domain.

The histone acetyltransferase p300 is also known as a transcriptional coactivator and
consists of several conserved domains involving acetyl-lysine binding bromodomain,
zinc-binding domain, and a centrally located HAT domain. These domains directly
interact with various cellular proteins and transcriptional factors

280

. The p300 HAT
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domain is organized as a central β-sheet containing seven β-strands surrounded by
loops and nine α-helices. This HAT domain can be further split into two subdomains,
a smaller C subdomain that comprises three α-helices and one β-strand that spans the
entire structure by covering the opposite ends of the larger N subdomain

[325]

. The

acetyl-CoA binding site of p300 resides located in a deep hydrophobic cavity that
extends into the interior of the protein. The back of the hydrophobic cavity is lined by
residues Ile1395, Tyr1397, Leu1398, and Ile1435. The larger number of interactions
and better binding affinity of acetyl-CoA could be attributed to its size. Among HATs,
the presence of an unusually long substrate-binding loop, L1, located between α4
and β5 is a feature unique to p300 and appears to encapsulate acetyl-CoA. In all the
acetyl-CoA structures of p300, Arg1410 bounded to the phosphates of acetyl-CoA by
a hydrogen bond. The significance of this interaction has been established by
mutagenesis and inhibition studies using 3′-dephospho-Lys-CoA

[326]

. Carnosol has

been found to occupy the same region where the pantetheine arm of acetyl-CoA is
bound. Both the pantetheine arm and lactone moiety made extensive interactions with
L1, the long loop. This kind of extensive interaction sequentially permits the L1 loop
to interact intramolecularly with other regions in p300’s HAT domain [327]. Carnosol
would fight with the incoming substrate in order to position it in the substrate-binding
grove of p300. In the substrate-binding loop, lysine residue contributed to the most
energetic interaction in the p300-carnosol complex. Altering this to alanine did not
cause any noteworthy change in the binding site and energy, demonstrating the
importance of the contribution of the whole loop in the binding of carnosol in p300.
Finally, carnosol binds to p300 with better binding energy than the known p300specific inhibitor C646 and the HAT inhibitor CPTH2.
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It is well reported that p300 functions as a coactivator of multiple transcription factors
to regulate the expression of many genes that control many biological processes
[328,329]

. Also, the HAT activity of p300, which is weak intrinsically, is stimulated by

the autoacetylation of some residues located in the HAT domain

[330]

. Here, the third

section of the study has shown that in addition to targeting p300 to degradation,
carnosol could inhibit the acetyltransferase activity required for autoacetylation and
acetylation of target proteins. The in silico molecular docking data and the competition
assay suggested that carnosol inhibits p300 activity by blocking the entry of acetylCoA into the active site and hence its autoacetylation, which further confirmed by in
silico molecular docking carried by Dr. Ranjit Vijayan. Several observations suggest
that the HAT activity of p300 is essential for its stability. Work by Jain and
collaborators revealed that autoacetylation is also crucial for p300 stabilization during
oxidative stress

[331]

, thus autoacetylation of p300 not only stimulates p300

transactivation function but also contributes to its stabilization. Indeed, these studies
showed that treating rat cardiac myocytes with ROS inducer, doxorubicin, led to p300
stabilization. Remarkably, the stabilization of p300, which reduces its resistance to
proteasome-degradation, was entirely due to an increase in the acetylation of p300 that
was dependent on its HAT activity. The half-life of p300 was reduced in the presence
of the inhibitor of p300, anacardic acid [331]. Also, curcumin, known to inhibit the HAT
activity of p300 selectively, induced oxidative stress and was reported to stimulate the
proteasomal-dependent degradation of p300

[241]

. Based on these observations, it

becomes tempting to hypothesize that the lack of p300 autoacetylation, due to the
inhibition of HAT activity, combined with oxidative stress could account, although
possibly not solely, for the targeting of p300 protein to proteasomal degradation. Al
Dhaheri et al. and Alsamri et al. have previously reported that carnosol induced a
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dramatic generation of ROS in triple-negative breast cancer cells, Hs578T and MDAMB-23 [50,323].

Here, section 3 of the study reported that carnosol inhibited p300 HAT activity and
promoted its proteasome degradation thru ROS generation. Additionally, it has been
showen that blockade of the proteasomal activity or ROS generation restored p300
protein that lacks HAT activity. Indeed, the rescue of p300 was not connected with the
restoration of acetylation of its preferred substrate, H3K56. Altogether, these results
support the hypothesis that one possible mechanism through which carnosol targets
p300 to degradation comprises the inhibition of p300 autoacetylation combined with
induction of oxidative stress in breast cancer cells.

An increasing body of evidence implies that p300 is a positive regulator of cancer
progression and is associated with tumorigenesis of various human cancers, including
the invasive MDA-MB-231 breast cancer

[216,218,332–334]

. It has been shown that

Knockdown of p300 reduced proliferation and caused a rise of caspase-dependent
apoptosis of both intrinsic and extrinsic apoptotic pathways in prostate cancer cells
[201]

. Moreover, the cellular invasion was decreased upon p300 depletion, which

reduced MMP-9 transcription

[201]

. Kim and coworkers exhibited that MMP-9

activation requires p300 and LYR71, a derivative of trimeric resveratrol, to reduce
MMP-9 transcripts via blocking p300 recruitment and deacetylating histone H3 and
H4 on the MMP-9 promoter

[249]

. Interestingly, Alsamri et al. showed that carnosol

inhibited the potential invasion of MDA-MB-231 by downregulating MMP-9
expression, targeting the transcription factor STAT3 to proteasome degradation

[323]

.

Herein, section 3 showed that carnosol dramatically reduced the level of p300 in
MDA-MB-231 breast cancer cells. Thus, p300 degradation may contribute to the
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downregulation of MMP9 and, therefore, inhibition of invasion of MDA-MB-231
cells.

The role of PCAF in tumorigenesis is somewhat controversial and seems to depend on
the type of cancer. PCAF was reported to function as a tumor suppressor in the case of
Hepatocellular carcinoma [230,335], gastric cancer [336], lung adenocarcinoma [337(p. 6)] and
colorectal cancer

[338]

while, in other cancers such as medulloblastoma and

glioblastoma, it contributes to cytoprotective events that help cancer cells to survive,
evade executing cell death programs and invade other tissues [339]. However, there are
only a few studies carried out on the role of PCAF in breast cancer. PCAF-mediated
acetylation at H3K9 at the multidrug resistance (MDR) genes was shown to contribute
to the multidrug resistance of breast cancer and, Knockdown of PCAF significantly
sensitizes these cancer cells to anticancer therapeutics [215]. Park et al. [340] showed that
pharmacological inhibition of PCAF by N-Acylanthranilic Acids [340]. Recently, Song
et al. showed that Acetylation of ARF6 GTPase-activating protein ACAP4 at Lys311
by PCAF is essential for the CCL18-elicited cell migration and invasion in MDA-MB231and MDA-MB-468 cancer breast cancer cells. Inhibition of PCAF activity by C146
(PCA inhibitor) abolished the acetylation of ACAP4 and consequently impaired the
migratory and invasive ability of MDA-MB-231 cells. Similar inhibition was observed
in PCAF-depleted MDA-MB-231 cells

[341]

. The inhibition of both p300 and PCAF

acetyltransferases activity was also shown to exert an anti-breast cancer effect. Indeed,
anacardic acid, an inhibitor of PCAF and p300 activity
arrest and apoptotic cell death in MDA-MB-231 cells

[236(p. 3)]

[342]

, induced cell cycle

. In addition, it was also

reported that anacardic acid efficiently and significantly inhibited cell migration and
invasion and downregulated the expression of MMP-9 in MDA-MB-231 cells [342,343].

100
Here, the results revealed for the first time that carnosol targets PCAF to ROSdependent proteasome degradation in breast cancer cells, which contribute to its
anticancer activity. The molecular mechanism by which PCAF is targeted to
degradation is yet to be uncovered. In agreement with the previous findings, our data
strongly suggest that PCAF contributes to breast cancer survival and/or metastasis and
represents a rational target for breast cancer therapy.
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Chapter 4: Conclusion

In this study, we investigated the efficacy of carnosol to inhibit breast cancer in vitro
and in vivo. Carnosol inhibited tumor growth derived from the triple-negative breast
cancer cells, MDA-MB-231. In addition, it significantly inhibited invasion and
metastasis via downregulating the activity and expression of MMP-9, inhibiting STAT3
signaling pathway through a ROS-dependent proteasome degradation of STAT3
protein. Moreover, carnosol has been shown to induce ROS-dependent ER stress
through upregulating the three main UPR sensors and their downstream targets which
includes ATF4/CHOP, ATF6⍺, and IRE1⍺/XBP1. Furthermore, we showed that
carnosol upregulated β-catenin while downregulating both Akt and mTOR. These later
proteins were targeted to ROS-dependent proteasome degradation. Interestingly, we
found carnosol-induced ER stress is dependent upon upregulation of the p38 MAPK
signaling pathway. Chemical inhibition of p38 dramatically reduced the level of CHOP
in carnosol-treated cells hence demonstrating the involvement of this pathway in the
induction of ER stress. A biochemical approach showed for the first time that carnosol
is a direct and selective inhibitor of the p300 histone acetyltransferase whose activity
was shown to mediate cancer invasion and metastasis. Finally, it is worth mentioning
that carnosol is a pharmacologically safe compound with no side effects observed in
different mice models. We propose the following model (Figure 19) to summarize the
mechanisms through which carnosol mediates anticancer activities against the triple
negative breast cancer.
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Figure 19: A hypothesized schematic model summarizing the possible mechanism of
action carnosol has in TNBC.
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Appendix

Cell lines/ Reagent / Antibodies /
rProteins
MDA-MB-231

Catalog No.

Manufacturer

300275

Hs578T
MCF7
T47D

HTB-126
HTB-22
300353

HCT116
DMEM, high glucose, pyruvate

CCL-247
41966029

RPMI 1640 Medium

21875034

Cell Line Service (CLS)GmbH, Germany
ATCC-USA
ATCC-USA
Cell Line Service (CLS)GmbH, Germany
ATCC-USA
Gibco™, Thermo
Scientific, UK
Gibco™, Thermo
Scientific, UK
Gibco™, Thermo
Scientific, UK
Gibco™, Thermo
Scientific, UK
Gibco™, Thermo
Scientific
Gibco, Life Technologies,
Rockville, UK
Sigma Aldrich, US
Abcam
Sigma-Aldrich

Fetal Bovine Serum (FBS), qualified, 10270106
Brazil
Penicillin-Streptomycin-Glutamine
10378016
(100X)
DPBS (1X)
14190094
Trypsin-EDTA (0.25%), phenol red

25200056

Carnosol
Chloroquine diphosphate
Autophagy Inhibitor, 3-MA
MG-132
Bortezomib
Caspase Inhibitor I (Z-VAD-FMK)
N-Acetyl-L-cysteine (NAC)
Trichostatin A (TSA)
goat anti-mouse IgG-HRP

C9617-5MG
ab142116
CAS 5142-234
2194
2204
187389-52-2
616-91-1
9950S
sc-2005

goat anti-rabbit IgG-HRP

sc-2004

β-Actin Antibody (C4)

sc-47778

Phospho-Stat3 (Tyr705)
Stat3 (124H6) Mouse
Anti-Histone H3 antibody
[EPR17785]
Acetyl-Histone H3 (Lys9/Lys14)
Anti-Histone H4, Acetylated (2-19)
Rabbit pAb
Anti-Histone H4

9131
9139
ab201456

Cell Signalling
Cell Signalling
Sigma Aldrich, US
Millipore
Enzo
Santa Cruz
Biotechnology
Santa Cruz
Biotechnology
Santa Cruz
Biotechnology
Cell Signalling
Cell Signalling
Abcam

9677
382160

Cell Signaling
Sigma Aldrich, US

07-108

Sigma Aldrich, US
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Anti-Histone H3 (acetyl K56)
antibody [EPR996Y]
Acetylated-Lysine
Acetyl-Histone H3 (Lys14) (D4B9)
Rabbit
Acetyl-Histone H3 (Lys9) (C5B11)
Rabbit
Anti-Histone H4 (acetyl K16)
antibody [EPR1004]
Acetyl-Histone H3 (Lys14) (D4B9)
Acetyl-Histone H3 (Lys9) (C5B11)
Rabbit mAb
Acetyl-Histone H4 (Lys5)
Anti-Histone H4 Antibody
Anti-Histone H4, Acetylated (2-19)
p300 Antibody (F-4)

ab76307

Abcam

9441
7627

Cell Signaling
Cell Signaling

9649

Cell Signaling

ab109463

Abcam

7627
9649

Cell Signaling
Cell Signaling

9672
07-108
382160
sc-48343

Acetyl-CBP (Lys1535)/p300
(Lys1499)
PCAF Antibody (E-8)

4771

Cell Signaling
Sigma Aldrich
Sigma Aldrich
Santa Cruz
Biotechnology
Cell Signaling

GCN5 Antibody (H-75)

sc-20698

Anti-acetyl-Histone H3
HDAC1 Antibody (H-51)

06-599
sc-7872

HDAC2 Antibody (C-8)

sc-9959

GAPDH Antibody (FL-335)

sc-25778

Recombinant Human STAT3 protein
p300 (catalytic domain) (human),
(recombinant)
Recombinant human Histone H3
protein
CREB binding protein (catalytic
domain) (human), (recombinant)
GCN5 (human), (recombinant)

ab43618
BML-SE4510100
ab198757

pCAF / Histone H3 (human) (5-23)
amide
Acetyl coenzyme A sodium salt, 5
mg
Core Histone Proteins
PMSF
40% Acrylamide/Bis 29:1 500ml
TEMED
APS (Ammonium Persulfate)

sc-13124

BML-SE4520100
BML-SE2720050
BML-P2710500
sc-210745A
13-107
36978
HC2040
17919
17874

Santa Cruz
Biotechnology
Santa Cruz
Biotechnology
Sigma Aldrich
Santa Cruz
Biotechnology
Santa Cruz
Biotechnology
Santa Cruz
Biotechnology
Abcam
Enzo
Abcam
Enzo
Enzo
Enzo
Santa Cruz
Biotechnology
Sigma Aldrich
Thermo scientific
Thermo Scientific
Thermo Scientific
Thermo Scientific
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PageRuler Plus Prestained Protein
Lader
Western Blot Stripping buffer 500ml
10x Tris-Glycine Buffer
Sodium Dodecyl Sulfate SDS
Trizma Base
Glycine
Mercaptoethanol
Tween™ 20

Digitally signed by
Shrieen
DN: cn=Shrieen,
o=United Arab
Emirates University,
ou=UAEU Library
Digitizatio,
email=shrieen@uaeu.a
c.ae, c=AE
Date: 2022.06.08
12:15:26 +04'00'

26619

Thermo Scientific

21059
28363
sc-264510c
T1503-1KG
G8898-1 KG
M6250-10ML
28320

Thermo Scientific
Thermo Scientific
chem cruz
SIGMA ALDRICH
SIGMA ALDRICH
SIGMA ALDRICH
Thermo Scientific™

